C-H9YFBooster Therapeutics
20S proteasome activation, small molecules, protein homeostasis
repairingsmall molecule
Loading
Loading section...0-100 chain-logic scale · 15 dimensions · scored on public evidence
←All companiesC-H9YF
C-H9YFC-H9YF20S proteasome activation, small molecules, protein homeostasis
0-100 chain-logic scale · 15 dimensions · scored on public evidence
%PDF-1.3 %��������� 4 0 obj > stream x�X�r7}�W�lvM ���zI (t"�~��������˫O��?Q��O�,��n(�Yz;�Ќ���N�؈v��V%��Jp�tC㽏9SN� i�8:51�-]߸g[��{���V�h�����6B��-�N�՝ 뻧ڞ�m���B/���}y����ah�a��#���C�'ھw�O� u�$Ҡ���R p�U�� ˸� �\x�X��i�?�z���hVn�ܞ��� CjCۣ���B�ML]���Y��o���Ί�6�w�ὡ���+m | "�O� �>����km�L��F��k�;頻m9a ��A%N7� �h���ͥ6e[Q}�1�jD���u'f�) �1��3�u�Z�5��a���[H:��&p� �5k�(��N :�[��I!��ބ��B#o���2�����$��C()�?n(�2 `x�)� x$�a�BhReRE�C�$Wc˞G��d�:߸�"�Z S�I!���{ ͩ��DُMn{�!y� B뎂�x�IXt ���3�� x"s��ʰqLZ0 �; �ba��O� �N� }�$���:�Aќ�.�$�����p�p"`��+�p��IҴNbQl�$#��X�20Qd9 … � �'"�� zY/3V���1�� � Gʷy}c�7��hYM?2� @�C�?M����jk�D���f�z� j�òQ��ڀ�?A��#k[RfP�.���h�Zœ�� o[M�5H�Z� � -1T��xDL����$1��A:�_��"c�X=��&ryc'��E���� �\f���cQ�b���'!W��R ^��4 ��שp�.p�D�^lM�,�\S*nh���B�:Ⱦ@~��n �| W yf�,�ι\�nT�Ȓ��q�_h�RK����鐫�/��5Y�S����>p�4�{2��K�K��ۜu[�g%_۠�ϴ�j.�q �r�M�m�L3ϸ R�Z������ե�^��.4��%KA���Or���6�0�p��&���w��� �U�^�1;��+�Ki��WTQ?��E�T?#� 0&�A= 3��:�� ��ti.1��S�z�dg��qT��M���qtu�� q M'j �]� V�hS,Mr l|������������X�o��� S
GeoVax Anticipates Significant 2025 Progress with Catalyst-Rich Milestones Across Key Programs - GeoVax, Inc. Accessibility Tools Invert colors Monochrome Dark contrast Light contrast Low saturation High saturation Highlight links Highlight headings Screen reader Read mode Content scaling 100 % Font size 100 % Line height 100 % Letter spacing 100 % (678) 384-7220 [email protected] About Us Company Leadership Board of Directors & Corporate Advisors Scientific Advisory Board Technology MVA Technology Overview Gedeptin® Technology Overview Publications Pipeline Pipeline Summary Oncology Infecti … UPDATES FROM GEOVAX Register to receive email alerts for GeoVax press releases SUBMIT Phone GeoVax © 2026 All Rights Reserved. Search About Us Company Leadership Board of Directors & Corporate Advisors Scientific Advisory Board Technology MVA Technology Overview Gedeptin® Technology Overview Publications Pipeline Pipeline Summary Oncology Infectious Diseases Investors Corporate Profile Press Releases Media Events & Presentations SEC Filings GeoVax Stock Information C
Valneva and Pfizer Report Positive Pediatric and Adolescent Phase 2 Booster Results for Lyme Disease Vaccine Candidate - Valneva Skip to content Valneva International Austria Canada France Sweden U.K. U.S.A. About Us About Us Advancing vaccines for better lives Learn More Our Strategy Our Expertise in Travel Health Our Sustainability Commitments Our Team Contact Products Products Focusing on vaccines for infectious diseases with major unmet needs Learn More Products Marketing and Distribution Manufacturing and Services R&D R&D Dedicated to innovation in vaccine research and development … y profile of VLA15 in the pediatric population, is also ongoing. Pfizer aims to submit a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) and Marketing Authorisation Application (MAA) to the European Medicines Agency (EMA) in 2026, subject to positive Phase 3 data. About VLA15 There are currently no approved human vaccines for Lyme disease, and VLA15 is the most advanced Lyme disease vaccine candidate currently in clinical development, with a … idens. 12 About Pfizer: Breakthroughs That Change Patients’ Lives At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products, including innovative medicines and vaccines. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, … ng unmet medical needs to ensure we can make a difference to peoples’ lives. We apply our deep understanding of vaccine science, including our expertise across multiple vaccine modalities, and our established vaccine development capabilities, to develop vaccines against diseases which are not yet vaccine-preventable, or for which there are limited effective treatment options. Today, we are leveraging our expertise and capabilities to rapidly advance a broad range of vaccines
On Tuesday afternoon,... - CBS 4 News Rio Grande Valley Facebook Log In CBS 4 News Rio Grande Valley's Post CBS 4 News Rio Grande Valley Verified account April 16 · Shared with Public On Tuesday afternoon, Booster 20’s forward dome with an integrated hot staging section was brought out of the star factory and parked in the ring yard area. valleycentral.com Latest at Starbase with LabPadre: April 16 All reactions: 9 1 comment Like Comment Most relevant Most relevant is selected, so some comments may have been filtered out.
XBRL Viewer Please enable JavaScript to use the EDGAR Inline XBRL Viewer.
%PDF-1.7 %���� 218 0 obj > endobj xref 218 55 0000000016 00000 n 0000002283 00000 n 0000002421 00000 n 0000002560 00000 n 0000002811 00000 n 0000002901 00000 n 0000003246 00000 n 0000003289 00000 n 0000003535 00000 n 0000003891 00000 n 0000004196 00000 n 0000004621 00000 n 0000004781 00000 n 0000004985 00000 n 0000006030 00000 n 0000006117 00000 n 0000008974 00000 n 0000009928 00000 n 0000010082 00000 n 0000010234 00000 n 0000011174 00000 n 0000011994 00000 n 0000012847 00000 n 0000013628 00000 n 0000014483 00000 n 0000015309 00000 n 0000015360 00000 n 0000016135 00000 n 0000016577 00000 n 000
2. BIOTECH SUMMIT AUSTRIA - LISAvienna - life science austria Jump to main content Newsletter Downloads EN DE About us Our Services Services at a Glance Information & Consulting Networking & Matching Expertise Marketing Funding On Raising Money Funding Opportunities Open Calls & Deadlines Private Equity Life Sciences in Vienna Interesting Facts For Start-ups Focusing on Biotech & Pharma Medical Devices made in Vienna Global market leaders Business Location Living and Working in Vienna News Events Home Events 2. BIOTECH SUMMIT AUSTRIA Back to overview Innsbruck, 10.10. - 11.10.2024 2. BIOTECH S
%PDF-1.6 %���� 668 0 obj > endobj xref 668 29 0000000016 00000 n 0000001592 00000 n 0000001658 00000 n 0000002132 00000 n 0000002159 00000 n 0000002294 00000 n 0000002858 00000 n 0000003363 00000 n 0000003620 00000 n 0000003657 00000 n 0000003914 00000 n 0000004028 00000 n 0000004666 00000 n 0000005483 00000 n 0000006276 00000 n 0000006904 00000 n 0000007576 00000 n 0000008285 00000 n 0000008540 00000 n 0000009091 00000 n 0000009770 00000 n 0000010576 00000 n 0000013234 00000 n 0000031750 00000 n 0000047835 00000 n 0000066334 00000 n 0000066405 00000 n 0000066469 00000 n 0000000876 00000 n tra … dobj 663 0 obj > endobj 664 0 obj > endobj 665 0 obj > endobj 666 0 obj >stream application/pdf PCS26_Sponsorship Prospectus_COMMUNITY_v04_Feb 13 2026 Adobe Illustrator 28.5 (Macintosh) 2026-04-08T11:11:13-04:00 2026-04-08T11:11:13-04:00 2026-04-08T11:11:13-04:00 256 100 JPEG /9j/4AAQSkZJRgABAgEASABIAAD/7QAsUGhvdG9zaG9wIDMuMAA4QklNA+0AAAAAABAASAAAAAEA
AQBIAAAAAQAB/+IMWElDQ19QUk9GSUxFAAEBAAAMSExpbm8CEAAAbW50clJHQiBYWVogB84AAgAJ
AAYAMQAAYWNzcE1TRlQAAAAASUVDIHNSR0IAAAAAA … 96 00000 n 0001733141 00000 n trailer ]>> startxref 116 %%EOF 666 0 obj >stream application/pdf The2026SUMMITSponsorshipProspectus Adobe Illustrator 28.5 (Macintosh) 2026-04-08T11:11:13-04:00 2026-04-08T11:17:05-04:00 2026-04-08T11:17:05-04:00 256 100 JPEG /9j/4AAQSkZJRgABAgEASABIAAD/7QAsUGhvdG9zaG9wIDMuMAA4QklNA+0AAAAAABAASAAAAAEA
AQBIAAAAAQAB/+IMWElDQ19QUk9GSUxFAAEBAAAMSExpbm8CEAAAbW50clJHQiBYWVogB84AAgAJ
AAYAMQAAYWNzcE1TRlQAAAAASUVDIHNSR0IAAAAAAAAAAAAAAAAAAPbWAAEAA
Instagram See everyday moments from your close friends . Log into Instagram Mobile number, username or email Password Log in Forgot password? Log in with Facebook Create new account Meta About Blog Jobs Help API Privacy Terms Locations Popular Instagram Lite Meta AI Threads Contact Uploading & Non-Users Meta Verified English Down chevron icon Afrikaans العربية Čeština Dansk Deutsch Ελληνικά English English (UK) Español (España) Español فارسی Suomi Français עברית Bahasa Indonesia Italiano 日本語 한국어 Bahasa Melayu Norsk Nederlands Polski Português (Brasil) Português (Portugal) Русский Svenska ภ
@geronsociety.bsky.social on Bluesky JavaScript Required This is a heavily interactive web application, and JavaScript is required. Simple HTML interfaces are possible, but that is not what this is. Learn more about Bluesky at bsky.social and atproto.com . Profile Gerontological Society of America geronsociety.bsky.social did:plc:pgiibbf6we3wvjx7oqv4dhkj Founded in 1945, we are the largest and most established interdisciplinary organization devoted to research, education, and practice in the field of aging.
Booster Therapeutics | Biotech Careers Skip to main content Biotech Careers Contact Submit an Employer Contact Add an Employer Search Open main menu Contact Submit an Employer Contact Add an Employer Search Main navigation Careers Job Areas People Articles Videos Biotech Companies Biotech Jobs Business Areas Booster Therapeutics Website: Booster Therapeutics Business Area(s) Small Molecules Description Develops small molecules to directly boost the activity of 20S proteasomes to restore the body’s ability to clear disease-causing proteins. Company Location(s) 10629 Berlin Germany body Si
Checking your browser - reCAPTCHA Checking your browser before accessing pmc.ncbi.nlm.nih.gov ... Click here if you are not automatically redirected after 5 seconds.
2. BIOTECH SUMMIT AUSTRIA | Agenda commit: da6163745208d443e289c1b5c68610b53559e711
Keynote: Patrick Trojer | BIOTECH AUSTRIA - Biotech --> Home Association Board Head Office Members Supporting Members Associate Members Events Membership News Login Home Association Board Head Office Members Supporting Members Associate Members Events Membership News Login 12.11.2024 Keynote: Patrick Trojer WE THANK OUR Supporting Members Biotech Austria BIOTECH AUSTRIA c/o Herbst Kinsky Rechtsanwälte GmbH Dr.-Karl-Lueger-Platz 5 1010 Wien [email protected] www.biotechaustria.org JA!BUCH 2022 JA!BUCH 2023 JA!BUCH 2024 PRESSE --> COPYRIGHT 2021 BIOTECH AUSTRIA Data Protection Impri
#bsa24 #biotech #innovation #keynotespeaker | BIOTECH AUSTRIA LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign in, you agree to LinkedIn’s User Agreement , Privacy
Keynote Patrick Trojer | BIOTECH AUSTRIA - Biotech --> Home Association Board Head Office Members Supporting Members Associate Members Events Membership News Login Home Association Board Head Office Members Supporting Members Associate Members Events Membership News Login 12.12.2024 Keynote Patrick Trojer WE THANK OUR Supporting Members Biotech Austria BIOTECH AUSTRIA c/o Herbst Kinsky Rechtsanwälte GmbH Dr.-Karl-Lueger-Platz 5 1010 Wien [email protected] www.biotechaustria.org JA!BUCH 2022 JA!BUCH 2023 JA!BUCH 2024 PRESSE --> COPYRIGHT 2021 BIOTECH AUSTRIA Data Protection Imprint
%PDF-1.4 %���� 1 0 obj /Creator (Chromium) /Producer (Skia/PDF m123) /CreationDate (D:20260505101358+00'00') /ModDate (D:20260505101358+00'00')>> endobj 3 0 obj > endobj 6 0 obj > stream x�}��JA��р( -,���"�E��J��6?�M�쎛m��e�� ���Nl|m}�B�T>Bb &�L��T�= .� ��2 �T�*������R�&�K��$�~ �����M0T� pt�m�({a�Ұ���4IA\֍��.P W�_a�h� ����wS �f�wv����p>������v�S� > stream x����oY����'�aԣe�T*�B#Y�Ҋ|b �4 r�ٜ-��4�U�;l�d��⦖a7�XZ$K�e��09ꅔKL�m�`�ی� ��.���L٬J��(6~|���?�}�jua߈'N�p��='>~}mke��m{{��s�. P;��ho��zǮ� b�qFm�ޱ��m��k7�.��:{���&k[��;��ZY����m.,. �ޱ�� YyeU��ƉZi\����+�?�
NMCS 2026 Confirmed Speakers LDO Conferences Home Committees Scientific Organizing Committee Program Program Confirmed Speakers Company Workshops Flash Poster Talks Division of Medicinal Chemistry Award IUPAC-Richter Prize Session Topics Networking Events Poster Sessions Registration My Registration Abstract Submission Abstract Guidelines Accommodation Sponsor-Exhibit Vendor Opportunities Confirmed Vendors Company Workshops Floorplans Practical Info Prices & Activities Sign up to emails Accommodation Atlanta Deadlines General Information Join MEDI Venue & Access FAQ General Terms and Condition … d Speakers Company Workshops Flash Poster Talks Division of Medicinal Chemistry Award IUPAC-Richter Prize Session Topics Networking Events Poster Sessions Registration My Registration Abstract Submission Abstract Guidelines Accommodation Sponsor-Exhibit Vendor Opportunities Confirmed Vendors Company Workshops Floorplans Practical Info Prices & Activities Sign up to emails Accommodation Atlanta Deadlines General Information Join MEDI Venue & Access FAQ General Terms and Condit … tween 2011-2020. He received the University of Michigan Distinguished Innovator Award in 2014, was elected Fellow of the National Academy of Inventors in 2014 and Fellow of the American Association for the Advancement of Science (AAAS) in 2019. He received the Division of Medicinal Chemistry Award of the American Chemical Society in 2020 and was inducted into Hall of Fame of the Division of Medicinal Chemistry, the American Chemical Society in 2020. Special Plenary Lecture Re … f of ACS Chemical Biology. Her honors and awards include a MacArthur Foundation Fellowship, a Guggenheim Fellowship, the ACS Gibbs Medal, the Tetrahedron Prize, the Centenary Prize of the Royal Society of Chemistry, and the Ronald Breslow Award for Achievement in Biomimetic Chemistry. MEDI Division Award 2026 MEDI Division Award Lecture A Perspective on Medicinal Chemistry on the Edge of Oral Druggable Space (AL01) Dr David DEGOEY ABBVIE INC., North Chicago, IL, United States … and earned a Ph.D. in organic chemistry from Harvard University. IUPAC-Richter Prize 2026 IUPAC-Richter Prize Lecture Protein Aggregation: The Basis for the Development of Akv9 as a Treatment for Neurodegenerative Diseases (AL02) Prof. Richard B. SILVERMAN NORTHWESTERN UNIVERSITY, Evanston, United States Read more Prof. Richard B. SILVERMAN &tim
Faculty – Page 4 – UC Irvine School of Pharmacy & Pharmaceutical Sciences Skip to content For Current Students Alumni Giving Partner With Us For Faculty & Staff Search Toggle search interface Search for... Search About Toggle "About" dropdown Our School Founding Dean Jan Hirsch School Leadership Offices & Staff Our Faculty Councils & Committees BEACoN Employment Departments Toggle "Departments" dropdown Department of Pharmaceutical Sciences Department of Clinical Pharmacy Practice Degrees & Programs Toggle "Degrees & Programs&qu … ornia Immunization Coalition’s Natalie J. Smith, MD, MPH, Immunization Champion Award June 25, 2025 Awards & Honors , Faculty , Research Dr. Alexandre Chan Awarded 2025 Susan & Henry Samueli College of Health Sciences (COHS) Faculty Assembly Basic Science COHS Team Research Award June 18, 2025 Faculty , In the Community , Students Albrecht Lab Hosted Lab Visit for Children with Cystinosis as Part of Cystinosis Research Foundation’s Day of Hope Family Conference June 5
Facebook Explore the things you love . Log into Facebook Email or mobile number Password Log in Forgot password? Create new account English (US) فارسی العربية Türkçe Deutsch Français (France) Polski More languages… Sign Up Log In Messenger Facebook Lite Video Meta Pay Meta Store Meta Quest Ray-Ban Meta Meta AI Instagram Threads Privacy Policy Privacy Center About Create ad Create Page Developers Careers Cookies Ad choices Terms Help Contact Uploading & Non-Users Meta © 2026
%PDF-1.7 %���� 1822 0 obj >stream hVmo�H�+�1U�k��E�* j��8m�">l���]d/w�~�ͬ1\ui.W�M�2�ׇggx�,` -�����g�a���� �VO�qp���]||>��� χ�^ )��2+��Ln��� q3`�)��Y�v^�F�,A>%�� i��#|�>6˄X�|����Uy]��}Qu�adk�[U��v�S��m�� aȧ��Z����6U�(��p3;XnfC�{ơ�V�Wt5ݘЕ\N9 ��qv��=!�OH���� ��m�����Hm�t�Z;� t���0���&p W0�׀@�f��w���=|��� hX�z�]kL-�Դ���ia��>Z)�� ��ofR�Q���#[���uO-��;� ��SuU�fUk����{�qZc�� �$��c��`q���K�iY�a��=�yl ��.��Ɵ�)�ȭ�5v��� ��p� endstream endobj 1823 0 obj >stream h�ܑ�j�0 �_EO0َ�6P]����һ� ���!��������t��'ϑ��I�R�-�Bn@���YR!�oc�A���@mt h�a�úY���� … OCESS 100.000000 CMYK 100.000000 69.999999 0.000000 20.000000 Adobe Illustrator application/postscript 2022-02-16_FREU_Weltkarte_2022_AG_FG_2 Gerhardt, Angela (F&Co.) default xmp.iid:5e19c940-baad-844f-8bb9-6f33287ea110 xmp.did:5e19c940-baad-844f-8bb9-6f33287ea110 uuid:3a58f6e6-330b-4e83-8803-9eebd9d58d37 xmp.iid:3784fcc6-7235-9741-a1ae-ad2e3c8963a9 xmp.did:3784fcc6-7235-9741-a1ae-ad2e3c8963a9 uuid:3a58f6e6-330b-4e83-8803-9eebd9d58d37 default saved xmp.iid:00393645-e4c9-e … N㷬X$�.���۾?M���ޝ$�0�Y����~w��nRw_M����8� endstream endobj 162 0 obj >stream application/postscript 2022_responsibiity_structure_CMYK (Bernd Fink) 2022-02-08T08:43:55+01:00 2022-02-08T08:43:55+01:00 2022-02-08T08:43:55+01:00 Adobe Illustrator 26.0 (Macintosh) xmp.iid:7d8e2075-9bb5-4615-9e5a-cb331d855b82 xmp.did:7d8e2075-9bb5-4615-9e5a-cb331d855b82 uuid:5D20892493BFDB11914A8590D31508C8 default xmp.iid:03a347a5-a2cb-4fd2-8f1b-3b29d950494e xmp.did:813149d3-0f62-4481-b52b-0b24 … 0 M=70 Y=0 K=20 PROCESS 100.000000 CMYK 100.000000 70.000000 0.000000 20.000000 application/postscript Volker Brinker watc_Logo_cmyk.eps converted from application/postscript to application/vnd.adobe.illustrator endstream endobj 264 0 obj >stream Working people with protection mask during corona virus pandemic. Industrial supervisor manager with hygienic mask controlling workers in production factory. occupation,foreman,hall,pandemic,manufacturing,worker,laborer,pr Copyright … �߬D���ϲ�oc�qD� ���=]�Қ�vD�A��%ŕ[w��˸�! v���ٴm�dyB���L�`��x�DY�ֲ >stream application/postscript 2021_06_09_Sustainability_Icons Gerhardt, Angela (F&Co.) 2021-11-17T10:16+01:00 2021-11-17T10:16+01:00 2021-11-17T10:15:59+01:00 Adobe Illustrator 26.0 (Windows) xmp.iid:e2100213-9f6b-204d-8f80-7f670aae01c0 xmp.did:e2100213-9f6b-204d-8f80-7f
DeepTechJobs .io European deep-tech companies hiring now Jobs Companies Pulse Map 438 roles 46 hiring 00 Contents Domain (Europe) All domains 438 Quantum 30 AI 121 Biotech 26 Space 145 Climate 36 Robotics 61 Advanced Materials 19 Track All tracks Research Engineering Operator Commercial Location All locations Europe-only roles Company stage All Seed Series A Series B Series C Public Jobs European deep-tech companies hiring now Scope Showing 0 roles for Europe-only locations filtered by "Booster Therapeutics" . The full dataset has 438 active roles at 46 European-headquartered compani
#boostertherapeutics #apollovc #parkinsonsresearch #biotech #lifesciences #innovation #proteostasis #neurodegeneration #michaeljfoxfoundation | Apollo Health Ventures LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree … herapeutics ! We’re proud to share that Booster Therapeutics has been awarded a grant from The Michael J. Fox Foundation for Parkinson's Research (MJFF) to advance the company’s novel class of proteasome activator medicines toward a first-in-human Phase 1 study. This recognition is a strong validation of Booster’s approach and its potential impact in neurodegenerative diseases. Booster is pioneering a new therapeutic strategy to counteract the accumulation of misfolded or abe … er assay window for robust and reproducible cell-based bioassay - Comprehensive application data to support assay development and validation - Full traceable record, stringent quality control and validated cell passage stability - Parental cell line legally obtained from internationally recognized cell resource bank and commercially licensed - Global commercial license assistance whenever regulatory filing is required. Explore the new collection: https://lnkd.in/emZYkQQg 1 Li
%PDF-1.7 %���� 1 0 obj > endobj 2 0 obj > endobj 3 0 obj >/Font >/XObject >/ProcSet[/PDF/Text/ImageB/ImageC/ImageI] >>/MediaBox[ 0 0 960 540] /Contents 4 0 R/Group >/Tabs/S>> endobj 4 0 obj > stream x��U�N1}_i�a�*/"��R��R�B�>T}�梒,l6 �G����&H���'��̙c�&�.��J� �T�5�2�~��,�N.,���� ��7/rZ��z����> ��ѷ8��H�F bM�],Ӗ� �@wG 8S.S�X��SJ�� �jU�jp�` � �N����`��O�K���� ,(A�q ���枿`�0�Z0��)�d�O �k� ��L ���Q}d��3�J|V>V�3[ax^� _m0�r�l�Vz�)�5�[>�ep�f5� ���� endstream endobj 5 0 obj > endobj 6 0 obj > endobj 7 0 obj > endobj 8 0 obj > endobj 9 0 obj > endobj 10 0 obj > endobj 11 0 ob … �2B� b�K�|��N#�O]�r �v�*��� {����v ��v���1zF��_���ٮ�s9W_-|�L����x �Ic#��RFP:�HT�p�� }�j=�+�u Ed=����8 �=4�DTQ*���bH�NH�2�ٯg������䈰ġ��9B8+�z�T`��D� ���i$�K2��K��\�'�µ�v� ��QEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQEQE �Q@ �֣��kW :���b(?x6 ��j�~�G���o%WlIn\H�Ca�t늺� Y�=B�칊y��4��u� � ���:=�����c`a����H]j2O� �����Β�����X_$H�2e^p>�+y��:��˽�� �,�cв�&�mɦ���-��P��H���x �P … hӸ]�>c�ڲ�4����>���ە��9H.�GP �� �ʜ��7N�����4y���t���3H �4MB���hV�ZwU�Y3�+ �rFp ��s��n�"�ɻ��ȸS�W̍�)���*���v������{�� ��������{�� P�� � "�EPYs���OJ�h����.�-BXu 5�B+:^P`_��:�p@�G��O�jSE�Z =��4wfD� *w� u*F�s�s� x�]�� ���檗��;Ɨ�t%����388#8���i��xv��{t��)�@�$��#�mQIh�Wq�R�D ���G��Ve���'���i�L}��Te I8��kQI�� ���+�G��j�,��� �*�H$�G$v�kV�O�-/�K�3NY � �7��8$tWYESw����G!�蓭���� k8�Y �*�z��,Z=�H�2�� *GB+F�w��q�'�5MKT3E�#T6m�(H\ �����5vc��� ��I6�"�` … x���Ak1����9&�q&�dw��UZ��v��҃h�.�n�m�����(hA(� f^�7o�� "�֘B�l���=�`��`�d��rFP���{�^�8{�l 4������U\GHC����rJUJ�Q��AQGX�0��E�7�d"2� � g7�)�ъ�u�Ēr�`�X�g�����,0�����j�a�2���Lƪ�hH�LŴ?��Q��פ���� ��Z��9 �'Ʌ��������A�Y�PZ�է�T�$�x���7M)�=�k?��u��-� �L�o^���>���� Y�� endstream endobj 2521 0 obj > stream ����JFIFHH��:ExifMM*QQ Q ��C !( !0*21/*.-4;[email protected]?]c\RbKSTQ��C''Q6.6QQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQ
JavaScript is disabled In order to continue, we need to verify that you're not a robot. This requires JavaScript. Enable JavaScript and then reload the page.
#tpd #inducedproximity #proteindegradation #innovation #healthcaresummit #neurodegeneration | Diogo R. Feleciano LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign i
JavaScript is disabled In order to continue, we need to verify that you're not a robot. This requires JavaScript. Enable JavaScript and then reload the page.
#farmers #efficient #computervision #ai #kenya #horticulture #floriculture #datadriven #algorithms #training #development #farming #agriculture #data | Jasper Simpkin | 21 comments LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept
#parkinsonsresearch #neuroscience #innovation #biotech #health #drugdiscovery | Diogo R. Feleciano | 45 comments LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign i … We’re honored to share that Booster Therapeutics has been awarded a $5 million grant from The Michael J. Fox Foundation for Parkinson's Research as part of its Therapeutics Pipeline Program 🧠 This support will help advance our new class of Proteasome activator medicines, designed to restore the cell’s natural ability to clear toxic proteins - a key driver of Parkinson’s and other complex, age-related diseases. Our approach directly activates 20S Proteasomes, enabling the br … 7mo Report this comment Congrats Diogo ! Looking forward to the outcomes of the grant! Like Reply 1 Reaction 2 Reactions Stephen P. Ducray, PhD 7mo Report this comment Congratulations Diogo! Like Reply 1 Reaction 2 Reactions Hugo Choupina 7mo Report this comment Parabéns! Like Reply 1 Reaction 2 Reactions Jose Ramalho 7mo Report this comment Congratulations! Well done! Like Reply 1 Reaction 2 Reactions See more comments To view or add a
Caring Brands expands global licensing deal | CABR 8-K Filing --> STOCK TITAN Login Sign up Login Sign up 0 HOME --> NEWS FEED Stock News Live Stock News Today Trending News AI news FDA Approvals Clinical Trials Crypto News Merger & Acquisitions Earnings Offerings IPO News Stock Splits Top News - Gainers Top News - Losers SEC FILINGS SEC Filings Live SEC Filings Today Form 4 - Insider Trading 8-K - Material Events 10-K - Annual Reports 10-Q - Quarterly Reports DEF 14A - Proxy Statements S-1 - IPO Registration S-3 - Shelf Registration STOCKS All Stock Themes AI Stocks Crypto Stocks Oil & Gas De
Booster Therapeutics (Booster Therapeutics GmbH) Javascript is disabled in your browser Startbase requires Javascript in order to display content. Please check your browser settings and enable Javascript-Support for this website. Your browser is outdated and Startbase will not be displayed correctly. Please use a modern web-browser like Mozilla Firefox , Google Chrome , Safari or Microsoft Edge . Startbase.com Database Startups Booster Therapeutics Magazine Magazine Topic Overview News Ticker Venture Clienting Focus News Interviews Reports Portraits Knowledge Base Database Startups Investors C
%PDF-1.6 %���� 97 0 obj > endobj xref 97 766 0000000016 00000 n 0000016758 00000 n 0000016937 00000 n 0000017062 00000 n 0000017097 00000 n 0000017388 00000 n 0000017517 00000 n 0000017662 00000 n 0000017684 00000 n 0000017814 00000 n 0000017959 00000 n 0000017981 00000 n 0000018112 00000 n 0000018257 00000 n 0000018279 00000 n 0000018410 00000 n 0000018556 00000 n 0000018578 00000 n 0000018797 00000 n 0000018943 00000 n 0000018965 00000 n 0000019184 00000 n 0000019329 00000 n 0000019351 00000 n 0000019528 00000 n 0000019676 00000 n 0000019698 00000 n 0000028980 00000 n 0000029933 00000 n 0000 … ��qm;�TB�`�����x� �=j��Ǔ��O�� d�L� 2A�+�,n� > endobj 164 0 obj >stream application/postscript Adobe Illustrator CS3 2010-11-10T17:24:36+05:30 2010-11-10T17:24:36+05:30 2010-11-10T17:24:36+05:30 256 48 JPEG /9j/4AAQSkZJRgABAgEASABIAAD/7QAsUGhvdG9zaG9wIDMuMAA4QklNA+0AAAAAABAASAAAAAEA
AQBIAAAAAQAB/+4ADkFkb2JlAGTAAAAAAf/bAIQABgQEBAUEBgUFBgkGBQYJCwgGBggLDAoKCwoK
DBAMDAwMDAwQDA4PEA8ODBMTFBQTExwbGxscHx8fHx8fHx8fHwEHBwcNDA0YEBAYGhURFRofHx8f
Hx8fHx8fHx8fHx8fHx8fHx … -08T20:21:55+05:30 Springer 2018-06-12T19:08:07+05:30 2018-06-12T19:08:07+05:30 application/pdf https://doi.org/10.1007/s13358-017-0139-4 Springer International Publishing Swiss Journal of Palaeontology, https://doi.org/10.1007/s13358-017-0139-4 Book review Marcelo R. Sánchez-Villagra 10.1007/s13358-017-0139-4 2010-04-23 true springer.com springerlink.com https://doi.org/10.1007/s13358-017-0139-4 10.1007/s13358-017-0139-4 1664-2384 137 1 109 112 journal Swiss Journal of Palae
Diogo R. - Profile - Couchsurfing Loading Share More © 2026 Couchsurfing International LLC Terms Privacy Sitemap Privacy Choices © 2026 Couchsurfing International LLC English English Diogo R. Not Verified Aracaju, Sergipe, Brazil @diogo-reis Member since 2013 0 Friends 0 References 0 Shared Locations 0 Upcoming Trips 1 Locations Lived 0 Locations Visited About References View All 0 Total 0 Travelers 0 Hosts 0 Personal
%PDF-1.7 %���� 1 0 obj >/Metadata 382 0 R/ViewerPreferences 383 0 R>> endobj 2 0 obj > endobj 3 0 obj >/ExtGState >/ProcSet[/PDF/Text/ImageB/ImageC/ImageI] >>/Annots[ 18 0 R 19 0 R 20 0 R 21 0 R 22 0 R 23 0 R 24 0 R 27 0 R] /MediaBox[ 0 0 612 792] /Contents 4 0 R/Group >/Tabs/S/StructParents 0>> endobj 4 0 obj > stream x��=ks�8��S���oK�lO��K��v��&�Y'3{��}Pd��"eH9���ow�AJ"e[������ ��O(9�5y������g ; ~�2��J.���iJ���Ǐ��$�?~t���3�p�1������z,�*�K��"y���#����)ƹJ�@� _���%}+ܷ ?�g��h���7����h_���ѾI�COO��>M��*��_��|��k���d���w�h��*Ћ}�P��ѾNO�Q���gឩ�6��� 5��m�#� C[�#! ����m�5,RP��@x����
--> Work | My Site top of page Rui Diogo Lab Biologist and Anthropologist Wanderer and Wonderer "Rui Diogo is becoming the Slavoj Zizek of evolutionary biology" Marcelo Sanchez Villagra "Science about, and for the excluded: an example in Uganda" Apart from being a research lab-based website, we step forward towards using state-of-the-art scientific data from the fields we study - mostly anthropology and biology - to address broader societal issues, communicate with the media and broader public, fight fictional narratives, prej
There have been so many things happening that I even forget them at times 😅. It has been so fulfilling and unexpected that I had to add these goals to my personal checklist even after they were… | Diogo R Duarte LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at an
Rui Diogo - Wikipedia Jump to content Main menu Main menu move to sidebar hide Navigation Main page Contents Current events Random article About Wikipedia Contact us Contribute Help Learn to edit Community portal Recent changes Upload file Special pages Search Search Appearance Donate Create account Log in Personal tools Donate Create account Log in Contents move to sidebar hide (Top) 1 Education 2 Work 3 Books Toggle Books subsection 3.1 Single author or co-author of the following books 3.2 Edited Books 4 Most relevant talks/science divulgation articles 5 References 6 External links Toggle th … of Liège ( PhD ) George Washington University ( PhD ) Awards Anatomical Society Award for Best Runner-Up Anatomical Paper (J. Anat.) in 2015 Outstanding Faculty Researcher Award of the Howard University College of Medicine in 2016/2017 Scientific career Fields Biology , anthropology , anatomy Institutions Howard University Rui Diogo is a Portuguese American biologist, researcher, speaker, and writer at Howard University with several published scientific books, [ 1 ] w … onservation, both in Africa (he is the current recipient and single PI of NSF's grant "Excellence in Research: The Visible Ape Project" (NSF, Award Number: 1856329) and Asia (he is the current recipient and single PI of NSF's grant "The Making of a University Hub for Basic Cultural Anthropological Research Related to Cultural and Biodiversity Conservation" (NSF, Award Number: 2309069). His groundbreaking research on these topics and on human evolution has gained widespread re … the Creative Commons Attribution-ShareAlike 4.0 License ; additional terms may apply. By using this site, you agree to the Terms of Use and Privacy Policy . Wikipedia® is a registered trademark of the Wikimedia Foundation, Inc. , a non-profit organization. Privacy policy About Wikipedia Disclaimers Contact Wikipedia Legal & safety contacts Code of Conduct Developers Statistics Cookie statement Mobile view Search Search Toggle the table of contents Rui Diogo Add languages
November 27, 2024 - 10-K: Annual report pursuant to Section 13 and 15(d) | Becton, Dickinson and Company (BDX) November 27, 2024 > Form 10-K > Becton, Dickinson and Company Document Links Form: 10-K Annual report pursuant to Section 13 and 15(d) November 27, 2024 Complete Filing PDF » Includes filing and all documents Documents 10-K » EX-4.CC » EX-10.D » EX-10.JI » EX-19 » EX-21 » EX-22 » EX-23 » EX-31 » EX-32 » EX-97 » 10-K: Annual report pursuant to Section 13 and 15(d) Published on November 27, 2024 0000010795 2024 FY FALSE P4Y P1Y … eding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☑ No ☐ Indicate by check mark whether the registrant is a "large accelerated filer," an "accelerated filer," a "non-accelerated filer," a "smaller reporting company," or an "emerging growth company." Large accelerated filer ☑ Accelerated filer ☐ Non-accelerated filer ☐ Smaller reporting company ☐ Emerging growth company ☐ If an emerging growth company, indicate by check mar … he legal manufacturer of BD Alaris™ infusion pumps. The Consent Decree does not apply to intravenous administration sets and accessories. Following an inspection that began in March 2020 of our Medication Management Systems facility in San Diego, California (CareFusion 303, Inc.), the FDA issued a Form 483 Notice (the “2020 Form 483 Notice”) that contained a number of observations regarding the site’s compliance with FDA’s Quality System, reporting of corrections and removals … s for Class III devices to which the non-conformances are reasonably related or grant requests for certificates to foreign governments. BD has worked closely with the FDA and implemented corrective actions to address the quality management system concerns identified in the Warning Letter. In March 2020, the FDA conducted a subsequent inspection of PAS, which it classified as 8 Table of Contents Voluntary Action Indicated, which means the FDA will not take or recommend any adm … DA will not approve any premarket submissions for Class III devices and may not grant requests for certificates to foreign governments concerning devices to which the non-conformances are reasonably related. As requested by the Dispensing Warning Letter, BD is preparing a comprehensive response to address FDA’s feedback in the Dispensing Warning
QL1001 - Drug Targets, Indications, Patents - Synapse Products Data Feature Plans Request Demo Sign Up for Free Last update 31 Jan 2026 QL1001 Last update 31 Jan 2026 Overview R&D Status Clinical Result Translational Medicine Deal Core Patent Clinical Trial Approval Regulation Overview Basic Info Drug Type Small molecule drug Synonyms Proteasome inhibitors (QLi5 Therapeutics) Target Proteasome Action inhibitors Mechanism Proteasome inhibitors Therapeutic Areas Neoplasms Immune System Diseases Hemic and Lymphatic Diseases Active Indication Autoimmune Diseases Solid tumor Hematologic Neoplas … .ema.europa.eu . In the U.S., the FDA accepted for review the Biologics License Application for linvoseltamab in adults with R/R MM with a target action date of July 10, 2025. About Multiple Myeloma As the second most common blood cancer, there are over 187,000 new cases of MM diagnosed globally every year, with more than 36,000 diagnosed and 12,000 deaths anticipated in the U.S. in 2025. In the U.S., there are approximately 8,000 people who have MM that has progressed after
Booster Therapeutics GmbH - Page 1 | BioWorld BioWorld. Link to homepage. BioWorld BioWorld Science BioWorld Asia Data Snapshots Biopharma Medical technology Infographics: Dynamic digital data analysis Index insights NME Digest Special reports Infographics: Dynamic digital data analysis BCI Ebola outbreak Hantavirus Trump administration impacts Med-tech outlook 2026 Under threat: mRNA vaccine research BioWorld at 35 Biopharma M&A scorecard Bioworld 2025 review BioWorld MedTech 2025 review BioWorld Science 2025 review Women's health China's GLP-1 landscape PFA re-energizes afib mark
BioWorld Science - Articles - Page 190 BioWorld. Link to homepage. BioWorld BioWorld Science BioWorld Asia Data Snapshots Biopharma Medical technology Infographics: Dynamic digital data analysis Index insights NME Digest Special reports Infographics: Dynamic digital data analysis BCI Ebola outbreak Hantavirus Trump administration impacts Med-tech outlook 2026 Under threat: mRNA vaccine research BioWorld at 35 Biopharma M&A scorecard Bioworld 2025 review BioWorld MedTech 2025 review BioWorld Science 2025 review Women's health China's GLP-1 landscape PFA re-energizes afib market Chin … Psychiatric Siteone's development of Nav1.8 inhibitor STC-004 supported by NIDA grant May 19, 2023 Siteone Therapeutics Inc. has been awarded a... Read More Neurology/Psychiatric Diamond Therapeutics describes new 5-HT2A receptor agonists May 18, 2023 Diamond Therapeutics Inc. has identified deuterated lisuride analogues acting as 5-HT2A receptor agonists reported to be useful for the treatment of neurological disorders. Read More Neurology/Psychiatric Polish researchers pres
AR-V7 Inhibitors(Arvinas) - Drug Targets, Indications, Patents - Synapse Products Data Feature Plans Request Demo Sign Up for Free Last update 08 Nov 2025 AR-V7 Inhibitors(Arvinas) Last update 08 Nov 2025 Overview R&D Status Clinical Result Translational Medicine Deal Core Patent Clinical Trial Approval Regulation Overview Basic Info Drug Type Small molecule drug Synonyms - Target AR-v7 Action inhibitors Mechanism AR-v7 inhibitors(androgen receptor splice variant 7 inhibitors) Therapeutic Areas Neoplasms Urogenital Diseases Active Indication Prostatic Cancer Inactive Indication - Originato … The partnership provides long-term financial support and accelerates real-world application of VantAI’s AI in drug design. The launch of Neo-1 represents a paradigm shift—transforming molecular glue development from serendipitous discovery to rational design. Blueprint’s reputation lends credibility to VantAI’s technology, while collaboration around undruggable targets will help build data and experience critical for VantAI’s internal pipeline, including proprietary glue prog … of 2025. If positive, we believe these results will support our first new drug application filing and our transition to a commercial-stage company, assuming regulatory approval.” “We are well on our way to becoming a multi-product, commercial-stage organization with strong leadership and a robust pipeline across several indications,” continued Dr. Houston. “Our first PROTAC degrader with the potential to treat neurodegenerative diseases, ARV-102, was recently cleared to init … restricted cash and marketable securities as of June 30, 2024, is sufficient to fund planned operating expenses and capital expenditure requirements into 2027. Second Quarter Financial ResultsCash, Cash Equivalents, Restricted Cash and Marketable Securities Position: As of June 30, 2024, cash, cash equivalents, restricted cash and marketable securities were $1,234.2 million as compared with $1,266.5 million as of December 31, 2023. The decrease in cash, cash equivalents, rest … e data from the VERITAC-2 clinical trial, submission of Arvinas’ first new drug application filing and transition to a commercial-stage company, assuming regulatory approval, the availability and timing of data from other clinical trials, the receipt of milestone and royalty payments in connection with the transaction with Novartis and the future
#biotechnology #innovation #longevity | Varun Malik LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign in, you agree to LinkedIn’s User Agreement , Privacy Policy ,
GSA Corporate Leaders Forum Main Menu Annual Scientific Meeting GSA Enrich GSA Connect KAER Reframing Aging My Dashboard Login Join Donate Membership Member Center Member Benefits Join Career & Learning Journals News & Events GSA News Calendar of Events Annual Scientific Meeting Press Room Advocacy Resources About Partner, Donate, Support, Advertise with GSA Board of Directors Sections and Committee Leaders GSA Staff and Career Opportunities Visiting Scholar and Executive Program Membership Member Center Member Benefits Interest Groups Join Career & Learning Journals News & Events GSA News GSA … mprove the health, well-being, and quality of life for older adults through the application of this interdisciplinary knowledge. GSA Corporate Leaders Forum Members Corporate Collaborators Corporate Leader Forum Resources Corporate Leaders Forum members collaborate to develop resources based on science to innovate practice on a variety of key topics and issues in gerontology, including brain health and dementia, ageism in health care, obesity and overweight, vaccine-preventab
GSA 2026 Annual Scientific Meeting: Welcome Main Menu Annual Scientific Meeting GSA Enrich GSA Connect KAER Reframing Aging My Dashboard Login Join Donate Home Registration Submissions Call for Abstracts Call for Reviewers Call for Workshop Applications Speakers Travel Program Exhibits & Sponsorship Experience National Harbor Home Registration Submissions Call for Abstracts Call for Reviewers Call for Workshop Applications Speakers Travel Program Exhibits & Sponsorship Experience National Harbor GSA 2026 Annual Scientific Meeting November 4 - 7 | National Harbor, MD Explore new research, fresh … ng Abstract Submissions—July 7 - August 13 Speaker Registration & Withdrawl Deadline—August 6 Early Bird Registration Closing—September 1 Late Breaking Abstract Acceptance/Non-Acceptance Notifications—Early October GSA 2026 by the Numbers 0 + Attendance 0 + Symposia 0 + Papers 0 + Posters Continuing Education for GSA 2026 Continuing education is being offered through a joint partnership between Postgraduate Institute for Medicine and Gerontological Society of America for … offer interactive, "hands-on" learning opportunities, that you can immediately apply in your work and research. Take advantage of these sessions and secure your spot today! Sign-up available on May 18 Reserve your Stay in National Harbor Take advantage of special rates negotiated exclusively for GSA 2026 attendees at the Gaylord National Resort & Convention Center. Be sure to register early as rooms are available on a first-come, first-served basis. Reserve Now See
Gerontological Society of America - GSA Main Menu Annual Scientific Meeting GSA Enrich GSA Connect KAER Reframing Aging My Dashboard Login Join Donate Membership Member Center Member Benefits Join Career & Learning Journals News & Events GSA News Calendar of Events Annual Scientific Meeting Press Room Advocacy Resources About Partner, Donate, Support, Advertise with GSA Board of Directors Sections and Committee Leaders GSA Staff and Career Opportunities Visiting Scholar and Executive Program Membership Member Center Member Benefits Interest Groups Join Career & Learning Journals News & Events … t-citizens: there is a need for you to make your voice heard in responding to a proposal that would give politically appointed officials authority over federal grant-making. This would represent a transformative shift in how grants are administered, with far-reaching implications, and we ask you to join with GSA in speaking up to both the presidential administration and Congress. --> June 24, 2026 GSA Launches New Web-Based KAER Toolkit for the Management of Obesity in Older
%PDF-1.7 %���� 1 0 obj >/Metadata 4543 0 R/ViewerPreferences 4544 0 R>> endobj 2 0 obj > endobj 3 0 obj >/ExtGState >/XObject >/ProcSet[/PDF/Text/ImageB/ImageC/ImageI] >>/MediaBox[ 0 0 612 792] /Contents 4 0 R/Group >/Tabs/S/StructParents 0>> endobj 4 0 obj > stream x��[Ko$'��4���n���iԒ��U���d ��a����N���R�����QӶ ���*(��}z$������'�n~���@�|y����mߓ��H��ne��'�h����|����� y�n���� �����\#F�pC'��T���ڼ�Б�� ��n>�!o'�?l7g'��톜� ��A >N���E��D��:9JZ�(����J�o���Av2����1m�WSX� ��j90�G��ZX:I�m�8g�N:cǓWc�3'�Lϻ}x���� �j�8����JSٕ�G�'��l䶴kc�DG�P� ��� ��+ :� �x����C��_?=|ᆜ�$i
%PDF-1.4 %���� 1 0 obj > endobj 3 0 obj > endobj 6 0 obj > stream x��]i�$9n�_�xh�$R�h�k��^����6����MF櫌� 3B f֖]x]�Y ��(. �����O��WZ|�����7���o_�� /��_~�r����������_�� ?�!��������/o��j�]h����9����#��O/��������{��_߾7�$��TL/a�EX��m�E ~�n��0{��R�w�,asisUW/����V�/��yY k��� ��� �^������������_ �|�˛��9�"���BL����S���J����_��x�yG?�חO���ç�A �i��= W��R��j���ο���CBWr���� � F�+ X���J��]z���)�l;��a� zF�c��ٍf�@Ib��O���N?Ln&����ޗjv��lF� �u1R�-/B�b��p0���� �a��U �H�NP���i����JJ����A�����'T �H�S��Qy��� ��Rc� �Ď76���E^��'���$Q\�I��wr�W��p8݂4n�c�����M�d�͇�m
Bionow BioAI Summit 2026 | Bionow on Glue Up This is a past event. Registration is closed. View other Bionow events. EN English Log In Close Please enter a valid email address e.g. [email protected] Email Address * If you input more than 0 characters your Email Address may not display properly Afghanistan | 🇦🇫 + 93 Aland Islands | 🇦🇽 + 358 Albania | 🇦🇱 + 355 Algeria | 🇩🇿 + 213 American Samoa | 🇦🇸 + 1684 Andorra | 🇦🇩 + 376 Angola | 🇦🇴 + 244 Anguilla | 🇦🇮 + 1264 Antarctica | 🇦🇶 + 672 Antigua and Barbuda | 🇦🇬 + 1268 Argentina | 🇦🇷 + 54 Armenia | 🇦🇲 + 374 Aruba | 🇦🇼 + 2 … input more than 0 characters your New Password may not display properly Cancel Submit Your password has expired. Change your password to continue. Password must be a minimum of 8 characters and contain at least one upper case letter, one lower case letter, one number , and one special character(!"#$%&'()*+,-./\:;?@[]^_`{|}~=) . Close Password must be a minimum of 8 characters and contain at least one upper case letter, one lower case letter, one number, and one special chara … input more than 0 characters your New Password may not display properly Cancel Submit Email Address Not Found Please go to My Profile and add an email address to continue with this action. Cancel
AI Summit - BIO International Convention 2026 Start your engines! BIO 2026 is June 22-25 at the San Diego Convention Center. Program announced! See the 130+ sessions in 18 focus areas. Generate Your Personal Event Schedule in Seconds! GENERATE NOW Start your engines! BIO 2026 is June 22-25 at the San Diego Convention Center. Program announced! See the 130+ sessions in 18 focus areas. Generate Your Personal Event Schedule in Seconds! GENERATE NOW June 22-25 | San Diego Event Info Event Overview About BIO International Convention Future dates Attendee Policies Schedule at a Glance FAQs In … ific Progress AI Implementation Biomanufacturing Academia Company Presentations Apply for a Company Presentation 2026 Presenting Companies Curated Programs AI Summit BIO Storytelling Stage BioProcess Theater Global Innovation Hubs Professional Development Courses Start-Up Stadium Student Program BIO Partnering™ BIO Partnering™ at BIO 2026 BIO Partnering™ Overview Pre-Event Webinars Partnering Resources LOG IN TO BIO PARTNERING Participating Companies All Partnering Companies … Amgen Genentech Boehringer Ingelheim Lilly Novo Nordisk Sanofi Academic Campus Apply for Academic Campus Exhibition Directory and Map Event Directory Exhibitor List Exhibitor In-Booth Events Event Map Exhibition Hours Exhibition Reception BIO Booths BIO Business Solutions® Pavilion BIO Member Lounge Networking BIO Receptions Other Events Social Spotlight Events Affiliate Events Application Special Experiences 5K and 1 Mile Course BIO Gives Back Headshot Lounge Matchday Loung … , high-fidelity genomic data, represents a major shift in how we understand and apply biology. Large-scale AI models trained on genomic and transcriptomic data enable researchers to predict biological behavior before running an experiment - accelerating discovery, improving clinical decision-making, and enabling more efficient d ... 3:00 PM – 4:00 PM AI Summit Session AI and Digital Health 28ABCDE Twitter LinkedIn Email Share Data Hunger, Enterprise Risks: Biomedical Data and
--> Life Extension News Archive Medical Technology 3D Printing AI in Healthcare Assistive Technology Digital Health Digital Modeling Laboratory Automation Nanotechnology in Healthcare Precision Medicine Robotic Surgery Synthetic Biology Health Antibiotic Resistance Big Pharma Cancer Diabetes Heart Disease Mental Health Musculoskeletal System Respiratory Disease Stroke Augmentation Artificial Organs Biohacking Brain Interface Exoskeleton Nootropics Prostheses Vision Life Extension Aging Research Anti-Aging Biological Age Calorie Restriction Cryonics Ethics Fountains of Youth Gene Therapy Immort … novia powers up mitochondrial medicine Longevity Technology - 01-Sep-2025 $350K grant fuels Minovia’s biomarker work, as early trials show promising patient gains Why turtles rarely get cancer Oxford Academic (OUP Academic) - 01-Sep-2025 Research shows turtles’ unique biology helps protect them from tumours despite long lifespans Rapamycin tops NIH review of anti-aging drugs UT Health San Antonio - 28-Aug-2025 Rapamycin extended mouse lifespan by up to 28%, even when given in … onger or weaker, offering new options for healing and repair Aubrai launches to fund longevity science with AI and blockchain CoinDesk - 25-Aug-2025 New DeSci platform uses tokens and AI to speed breakthroughs in ageing research World-first lab breakthrough creates living human skin Interesting Engineering - 22-Aug-2025 New model could transform treatments for burns, wounds, and chronic skin disorders AI-powered proteins unlock faster stem cell breakthroughs OpenAI - 22-Aug-2 … 40 million to support longevity research Longevity Technology - 18-Jul-2025 The fund bridges East-West collaboration and acts quickly using its own capital Brain activity sheds light on why we persist or give up when mentally tired Johns Hopkins Medicine - 17-Jul-2025 Study links two brain areas to cognitive fatigue and motivation during demanding mental tasks Long-term obesity makes young adults biologically older Live Forever Club - 16-Jul-2025 Staying healthy young can kee … diterranean countries age faster than those in northern and western Europe Mito Fund invests in Pretzel Therapeutics for mitochondrial disease therapies Longevity Technology - 15-Jul-2025 New investment fuels development of therapies targeting mtDNA-related energy disorders Iron overload: how aging muscles rust from within UW School of Medicine a
Machine Learning for Health (ML4H) | Broad Institute Skip to main content Top menu Careers Giving Intranet Search Show results from www.broadinstitute.org intranet.broadinstitute.org All About us This is Broad Learn about our mission, values, and history. Our impact Discover the impact of our research on human health. Our focus areas Learn about Broad’s main areas of research. People Meet our members, staff scientists, fellows, leadership, and other Broadies. Join Broad Find out how to join the Broad as an employee or associate member. Contact us Find our contact information, directions to our … ad_ml4h on X or join our mailing list . Latest news News 06.15.2026 2026 Merkin Prize in Biomedical Technology awarded to pioneers of the modern cochlear implant News 06.15.2026 Scientists improve nearly every aspect of prime editing, moving it closer to treating more genetic diseases News 05.13.2026 Precision DNA editing targets root cause of severe childhood epilepsy in preclinical study News 05.01.2026 Single-molecule tracker illuminates workings of cancer-related proteins
NeurIPS 2024 - Microsoft Research Skip to main content Research Publications Code & data People Microsoft Research blog Artificial intelligence Audio & acoustics Computer vision Graphics & multimedia Human-computer interaction Human language technologies Search & information retrieval Data platforms and analytics Hardware & devices Programming languages & software engineering Quantum computing Security, privacy & cryptography Systems & networking Algorithms Mathematics Ecology & environment Economics Medical, health & genomics Social sciences Technology
Machine Learning for Health (ML4H): Advancing Healthcare for All NeurIPS 2020 CSP Test --> Skip to yearly menu bar Skip to main content Main Navigation NeurIPS Help/FAQ Contact NeurIPS Create Profile Code of Ethics Code of Conduct Journal To Conference Track Diversity & Inclusion Proceedings Future Meetings Press Exhibitor Information Privacy Policy Downloads My Stuff Login Select Year: (2020) 2026 2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007 2006 Earlier Conferences Getting Started Schedule Featured Invited Talks Outstanding Paper Awards A … Beaulieu-Jones ⋅ Danielle Belgrave ⋅ Tristan Naumann Project Page Abstract The application of machine learning to healthcare is often characterised by the development of cutting-edge technology aiming to improve patient outcomes. By developing sophisticated models on high-quality datasets we hope to better diagnose, forecast, and otherwise characterise the health of individuals. At the same time, when we build tools which aim to assist highly-specialised caregivers, we limit
ML4H Home About History Past Events Organizing Committee Governing Board Sponsor Submit Call for Papers Call for Demonstrations Mentorship Programs Attend Schedule Speakers Research Roundtables Plan Your Visit Resources Writing Guidelines Reviewing Guidelines Community Guidelines Code of Conduct Review Policy Publication Ethic FAQs Job Board Home About History Past Events Organizing Committee Governing Board Sponsor Submit Call for Papers Call for Demonstrations Mentorship Programs Attend Schedule Speakers Research Roundtables Plan Your Visit Resources Writing Guidelines Reviewing Guidelines C … e Westin San Diego Gaslamp Aug 1: Submission site opens Sep 8: Paper submission deadline Oct 27: Decisions released Please direct any questions to [email protected] For announcements, follow us on Twitter @symposiumml4h 24 Speakers 2.5k Attendees 80 Awards Schedule Registration Sponsors Diamond Gold Silver Design & Developed by ThemesPride Back to Top
TRIANA Biomedicines closes $120M Series B funding round | The Pharmaletter Thursday 25 June 2026 About Contact Login VC & Investment M&A AI Podcasts News Pharmaceutical News Biotechnology News Generics News Biosimilars news In Brief Legal Company Pages In The Boardroom Insights Analysis Special Report Interviews Expert View From Our Correspondent One To Watch Companies Digital Pharma Pharma Leaders Regulatory FDA EMA Pricing, Reimbursement and Access Regulation Government Affairs Trump Administration Therapy Areas Dermatologicals Oncology Neurological Rare Diseases Hematology Cardio Va … with Lilly 24 June 2026 Biotechnology Ollin Bio lands $330 million Series B to fund late-stage retinal disease studies 24 June 2026 Biotechnology 105M upfront for Antares in Novartis deal 24 June 2026 Biotechnology EC backs Padcev-Keytruda combination before and after surgery in bladder cancer 24 June 2026 Biotechnology Combotope Thera enters collaboration with Boehringer 24 June 2026 Biotechnology Osanni Bio raises $190 million Series B to advance therapeutics platform 24 J … collaboration with Lilly 24 June 2026 Ollin Bio lands $330 million Series B to fund late-stage retinal disease studies 24 June 2026 105M upfront for Antares in Novartis deal 24 June 2026 EC backs Padcev-Keytruda combination before and after surgery in bladder cancer 24 June 2026 The Pharma Letter 39-43 Putney High Street, Putney London, SW15 1SP United Kingdom About us Contact Subscribe Sponsorship/advertising Company News Directory Terms and Conditions Privacy Policy Twitte
Booster Therapeutics–Novo Group: investment, 202410 seed financing round totalling $15m incl co-lead investor Novo Holdings - [LSE] Life-Sciences-Europe.com - The European Life Sciences Web Portal Zum Inhalt News People Events Deals Organisations Newsletter About us Contact Top News AMD, Dell & Univ Cambridge Launch UK AI Innovation Lab Caszyme: WiFIX Consortium Awarded €1m Eurostars Grant GSK to Acquire Nuvalent for $10.6b in Cash Merck Appoints Two Life Sciences Leadership Team Members Fusix Biotech & Recipharm Advance Oncolytic Virus Platform Roche and Nurix: up to $2.3b Agreement for BTK D … to Biosciences and DaltonTx: AI-Driven Collaboration » More News! » Submit your News! Upcoming Events UBS Life Sciences Conference 2026 London Metabolomics 2026 Buenos Aires BIO 2026 San Diego (BIO International Convention) TD Cowen’s Tools/Dx Revolution Conference 2026 Dana Point Truist Securities Healthcare Disruptors & Digital Health Conference 2026 New York LSI Asia ’26 Emerging MedTech Summit 2026 Singapore Longevity Summit Dublin 2026 European Spatial Comput … f America Global Healthcare Conference London 2026 » More Events! » Submit your Event! Management Appointments Endress+Hauser Appoints Christian Mäder as Future CFO Orlando Oliveira Succeeds Dario Eklund as CEO of Santhera Clara Sattler de Sousa e Brito Joins Merck (DE) from Philips Evotec Nominates Dieter Weinand as Supervisory Board Chair Santhera Appoints Marc Clausse as Chief Commercial Officer Fujifilm Biotechnologies Appoints Christiane Bardroff as CBO Camil … n Bulling Joins ProBioGen as Chief Operating Officer » More News! » Submit your News! Financings & Acquisitions Ona Therapeutics Raises $86.6mSeries B to Advance ADCs Olix Pharma Secures KRW110b Investment from BOLD and Weiss T-Curx GmbH Acquires Pantherna Therapeutics GmbH Genovis Acquires KPL ApS for DKK30.5m Upfront plus Earn-outs Lilly to Acquire LimmaTech Biologics for up to $780m in Cash InSphero Acquires PhenoVista Biosciences to Expand in US Lauxera Capita … henoVista Biosciences to Expand in US Lauxera Capital Partners Closes Growth II Fund at €520m Metis TechBio: $270m IPO at Hong Kong Stock Exchange NanoStruct Closes €2.6m Seed Round Led by HTGF et al. Roche to Acquire PathAI for up to $1.05b » More News! » Submit your News! Collaborations & Licensing Roche and Nurix: up to $2.3b Agree
proteasome activator n. a. - [LSE] Life-Sciences-Europe.com - The European Life Sciences Web Portal Zum Inhalt News People Events Deals Organisations Newsletter About us Contact Top News AMD, Dell & Univ Cambridge Launch UK AI Innovation Lab Caszyme: WiFIX Consortium Awarded €1m Eurostars Grant GSK to Acquire Nuvalent for $10.6b in Cash Merck Appoints Two Life Sciences Leadership Team Members Fusix Biotech & Recipharm Advance Oncolytic Virus Platform Roche and Nurix: up to $2.3b Agreement for BTK Degrader AMD Commits up to £2b to Accelerate AI in UK DaltonTx Launches Platform and Partners with … to Biosciences and DaltonTx: AI-Driven Collaboration » More News! » Submit your News! Upcoming Events UBS Life Sciences Conference 2026 London Metabolomics 2026 Buenos Aires BIO 2026 San Diego (BIO International Convention) TD Cowen’s Tools/Dx Revolution Conference 2026 Dana Point Truist Securities Healthcare Disruptors & Digital Health Conference 2026 New York LSI Asia ’26 Emerging MedTech Summit 2026 Singapore Longevity Summit Dublin 2026 European Spatial Comput … f America Global Healthcare Conference London 2026 » More Events! » Submit your Event! Management Appointments Endress+Hauser Appoints Christian Mäder as Future CFO Orlando Oliveira Succeeds Dario Eklund as CEO of Santhera Clara Sattler de Sousa e Brito Joins Merck (DE) from Philips Evotec Nominates Dieter Weinand as Supervisory Board Chair Santhera Appoints Marc Clausse as Chief Commercial Officer Fujifilm Biotechnologies Appoints Christiane Bardroff as CBO Camil … n Bulling Joins ProBioGen as Chief Operating Officer » More News! » Submit your News! Financings & Acquisitions Ona Therapeutics Raises $86.6mSeries B to Advance ADCs Olix Pharma Secures KRW110b Investment from BOLD and Weiss T-Curx GmbH Acquires Pantherna Therapeutics GmbH Genovis Acquires KPL ApS for DKK30.5m Upfront plus Earn-outs Lilly to Acquire LimmaTech Biologics for up to $780m in Cash InSphero Acquires PhenoVista Biosciences to Expand in US Lauxera Capita … henoVista Biosciences to Expand in US Lauxera Capital Partners Closes Growth II Fund at €520m Metis TechBio: $270m IPO at Hong Kong Stock Exchange NanoStruct Closes €2.6m Seed Round Led by HTGF et al. Roche to Acquire PathAI for up to $1.05b » More News! » Submit your News! Collaborations & Licensing Roche and Nurix: up to $2.3b Agree
20S proteasome activation gets $15M to fight neurodegeneration Skip to content Search for: Suggested Topics: Categories Browse by resource or article category Knowledge hub Resources Biotech funding tracker Biotech deals tracker Biotech layoff tracker Biotech events 2026 List of biotech grants Biotech associations Categories News and Trends In-depth Best in Biotech Podcasts Top Pharma Strategy Opinion Expert Advice Sponsored Mending university and venture capital relations: is it possible to see eye-to-eye? Portugal: will the life science sector see upswing amid funding worries? Sectors Browse … t after Novo Holdings led Asceneuron’s $100 million series C round, and now the fund has invested in another company showing great promise for treating neurodegenerative diseases, but with what seems to be a wider scope. “Booster’s differentiated approach to clearing damaged proteins was unlike any other approaches we had seen within the protein degradation space. That, together with their data, convinced us,” said Joao Ribas, the investor in charge of Booster Therapeutics at
Instagram See everyday moments from your close friends . Log into Instagram Mobile number, username or email Password Log in Forgot password? Log in with Facebook Create new account Meta About Blog Jobs Help API Privacy Terms Locations Popular Instagram Lite Meta AI Threads Contact Uploading & Non-Users Meta Verified English Down chevron icon Afrikaans العربية Čeština Dansk Deutsch Ελληνικά English English (UK) Español (España) Español فارسی Suomi Français עברית Bahasa Indonesia Italiano 日本語 한국어 Bahasa Melayu Norsk Nederlands Polski Português (Brasil) Português (Portugal) Русский Svenska ภ
- YouTube Info Presse Urheberrecht Kontakt Creator Werben Entwickler Impressum Verträge hier kündigen Nutzungsbedingungen Datenschutz Richtlinien & Sicherheit Wie funktioniert YouTube? Neue Funktionen testen © 2026 Google LLC
The Revolution Against Aging and Death (RAAD) Festival – Fight Aging! Home FAQ Fund Research Services Investing Therapies Newsletter Archives Press Room Resources About Fight Aging! Do you want to live a longer life in good health? Simple practices can make some difference, such as exercise or calorie restriction. But over the long haul all that really matters is progress in medicine: building new classes of therapy to repair and reverse the known root causes of aging. The sooner these treatments arrive, the more lives will be saved. Find out how to help » April 25th, 2016 The Revo … Living Longer Read the Fight Aging! FAQ Sign up for the Fight Aging! Newsletter Fund Meaningful Aging Research Services Longevity Industry Consulting How to Start a Longevity Biotech Company The Root Causes of Aging Aging is Caused by Damage Accumulating Cross-Links Buildup of Amyloid Between Cells The Failing Adaptive Immune System The Failing Innate Immune System Declining Lysosomal Function Mitochondrial DNA Damage Nuclear DNA Damage Buildup of Senescent Cells Archives and … Feed RSS Comments Feed Using the Fight Aging! Content Feeds Required Reading A Proposal to Accelerate Progress Calorie Restriction and Longevity Cryonics, the Necessary Backup Plan How to Argue for Longevity Science The Odds of Human Longevity Mutations The Need For Activism and Advocacy Nuanced Opposition to the FDA Potential Gene Therapy Targets Predicting the First Rejuvenation Therapies Self-Experiment to Fight Aging! SENS: Bringing an End to Aging Stem Cells and Regener … ht Aging!. Home | FAQ | Fund Research | Services | Investing | Therapies | Newsletter | Archives | Press Room | Resources | About Read our terms and conditions and privacy poli
RAADcity Expo 2026 | Longevity Products, Services & Exhibitors at RAADfest — RAADfest 0 Skip to Content Home 2026 Speakers 2026 Location & Hotel Press RAADcity Expo & Sponsors Prev RAADfest 2025 Video Library 2025 Speakers 2024 Speakers RAADfest 2024 Video Library 2023 Speakers 2022 Speakers About FAQ Contact Us Register for 2026 Open Menu Close Menu Register for 2026 Home 2026 Speakers 2026 Location & Hotel Press RAADcity Expo & Sponsors Prev RAADfest 2025 Video Library 2025 Speakers 2024 Speakers RAADfest 2024 Video Library 2023 Speakers 2022 Speakers About FAQ Cont … commitment to life extension advancements. Become a Sponsor for RAADfest 2026. Submit your application today. Submit Application Become a Sponsor for RAADfest 2026. Submit your application today. Submit Application Become a Sponsor for RAADfest 2026. Submit your application today. Submit Application Become a Sponsor for RAADfest 2026. Submit your application today. Submit Application Join us at RAADfest and position your longevity protocol at the forefront of the super longe … nce. Ray Searles- Life Extension Foundation Become a Sponsor for RAADfest 2026. Submit your application below. Sponsors representing businesses and organizations relevant to the life extension and longevity fields are invited to participate. In addition to boosting your brand with consumers and influencers, your sponsorship helps us support the advancement of radical life extension.Apply now to secure your place! Submit your application All submissions are reviewed and approv
RAADfest 2026 | The World's #1 Longevity Conference | Sept 4-6, Scottsdale, AZ 0 Skip to Content Home 2026 Speakers 2026 Location & Hotel Press RAADcity Expo & Sponsors Prev RAADfest 2025 Video Library 2025 Speakers 2024 Speakers RAADfest 2024 Video Library 2023 Speakers 2022 Speakers About FAQ Contact Us Register for 2026 Open Menu Close Menu Register for 2026 Home 2026 Speakers 2026 Location & Hotel Press RAADcity Expo & Sponsors Prev RAADfest 2025 Video Library 2025 Speakers 2024 Speakers RAADfest 2024 Video Library 2023 Speakers 2022 Speakers About FAQ Contact Us Open M … longer. Science-Based, Not Hype-Based Every speaker is selected for real-world application, not buzz. This is the science that's working now. Accessible RAADfest attendees have direct access to speakers, real conversations, and connections that don't happen at other events. Not-for-profit Mission RAADfest is produced by the Coalition for Radical Life Extension , a 501(c)(3) not-for-profit. The mission is the movement, not the margin. A Decade of Impact Launched 2016, RAADfes
Booster launches with $15M, new approach in proteasome activation | BioWorld BioWorld. Link to homepage. BioWorld BioWorld Science BioWorld Asia Data Snapshots Biopharma Medical technology Infographics: Dynamic digital data analysis Index insights NME Digest Special reports Infographics: Dynamic digital data analysis BCI Ebola outbreak Hantavirus Trump administration impacts Med-tech outlook 2026 Under threat: mRNA vaccine research BioWorld at 35 Biopharma M&A scorecard Bioworld 2025 review BioWorld MedTech 2025 review BioWorld Science 2025 review Women's health China's GLP-1 lands
Aging Companies (for profits) - Google Sheets Die Datei kann in Ihrem Browser nicht geöffnet werden, weil JavaScript nicht aktiviert ist. Aktivieren Sie JavaScript und laden Sie die Seite noch einmal. Diese Browserversion wird nicht mehr unterstützt. Installieren Sie bitte einen unterstützten Browser. Aging Companies (for profits) Tab Extern Freigeben Anmelden Datei Bearbeiten Ansicht Einfügen Format Daten Tools Erweiterungen Hilfe Bedienungshilfen Fehlerbehebung Nicht gespeicherte Änderungen in Drive &n … NA interference (RNAi) therapieus to silence disease-specific genes, with broad application to many age-related disease areas FDA approved Tx proteostasis (h)ATTR(-CM), AD, HD, ALS, T2D, MASH, NAFLD, hypercholesterolemia, hypertension humans 82 ATTR, APP, PCSK9, AGT, HTT, SOD-1, HSD17B13 siRNA pharma Yvonne Greenstreet, Kevin Fitzgerald Boston yes ALNY $39,261 2100 2442 2002 >$100M Onpattro, Amvuttra, Leqvio science presentations 2025-02-02 2024-08-15 *Borderline: Broad pr
News > Denmark - [LSS] Life-Sciences-Scandinavia.com - The Scandinavian Life Sciences Web Portal Zum Inhalt News People Events Deals Organisations Newsletter About us Contact Top News Caszyme: WiFIX Consortium Awarded €1m Eurostars Grant Roche and Nurix: up to $2.3b Agreement for BTK Degrader Fusix Biotech & Recipharm Advance Oncolytic Virus Platform Lundbeck & Cradle Partner for AI-based Brain Disorder R&D Genovis Acquires KPL ApS for DKK30.5m Upfront plus Earn-outs Cytospire Therapeutics: £61m Series A Led by 4BIO Capital Windward Bio: $165m Crossover Financing Led by OrbiMed Leo Pharma to A … ly Adcendo Closes $75m Series C Led by Jeito Capital » More News! » Submit your News! Upcoming Events Metabolomics 2026 Buenos Aires BIO 2026 San Diego (BIO International Convention) EUROMAR 2026 Gothenburg (Göteborg) bio:cap Investival 2027 Berlin (BioCap 2027) World Health Expo Osaka 2026 (WHX Osaka 2026) ISSCR 2026 Montréal ADLM 2026 Annual Meeting & Clinical Lab Expo Anaheim DxPx U.S. Conference 2026 Anaheim IMSC 2026 Lyon European Conference on Computational … th Annual Healthcare Conference 2027 San Francisco » More Events! » Submit your Event! Management Appointments Fujifilm Biotechnologies Appoints Christiane Bardroff as CBO Medivir AB Appoints Patrik Norgren as CFO Gubra Launches Gubra Ventures, Headed by Zoë Johnson Kaffe Bueno Appoints Thomas Durhuus as CEO Bico Names Jesper Hagberg Chief Operations & Digital Officer Bico Appoints Ewa Linsäter as CFO, Jacob Thordenberg Leaves Séverine Lemoine New General Manager … points Fraser McLeod as Managing Director of Biosero » More News! » Submit your News! Financings & Acquisitions Genovis Acquires KPL ApS for DKK30.5m Upfront plus Earn-outs Lauxera Capital Partners Closes Growth II Fund at €520m Leo Pharma to Acquire Gene Therapy Company Replay CARB-X Awards Funding to AdJane to Advance Gonorrhea Vaccine Coultreon’s $125m Series A Is Led by Sofinnova Investments Proteins.1 Raises €4.7m in Pre-Seed Funding to Pioneer Omics Roche to … $595m Adcendo Closes $75m Series C Led by Jeito Capital CubaseBio Receives €2m Grant from EI Transition Programme Aerska Raises $39m Series A Led by EQT and age1 » More News! » Submit your News! Collaborations & Licensing Fusix Biotech & Recipharm Advance Oncolytic Virus Platform Lundbeck & Cradle Partner for AI-based Brain Disorder
age1’s 2025 1st Annual Pharma Aging Report Card Subscribe Sign in age1’s 2025 1st Annual Pharma Aging Report Card Grading the giants on their race to extend human healthspan age1 and Soleil Wizman Jul 29, 2025 26 4 Share Only decades ago, aging research remained a niche curiosity sequestered to a handful of academic labs across the world. But long gone are the days when longevity was a fringe pursuit struggling for funding and mainstream attention. Today, top pharma companies are pouring millions into trials, partnerships, and acquisitions in the longevity space, signaling a fundamental shift … e brain tissue is still salvageable. On the investment front, the Roche Venture Fund committed $290 million in 2022 to Freenome , an SF-based company developing machine learning-enabled multiomics blood tests to detect colorectal and lung cancers at their earliest stages. And in 2023, Roche partnered with Alnylam Pharmaceuticals to commercialize zilebesiran, an RNAi therapeutic reducing liver angiotensinogen mRNA levels to lower blood pressure. Roche also recently acquired Ca … Smart Healthy Aging QuickFire Challenge , which invites Japan-based founders to submit promising science or technologies with the potential to increase healthy life expectancy. J&J committed $300,000 in grant funding, lab access, and mentorship to four startups. While J&J’s commitment to aging in the Asia Pacific region had long evaded the U.S., the New Jersey-based corporation has recently begun employing scientists to research aging and metabolism in its home countr … $80 million in exchange for an option to buy out the company at the time of IND application submission. Earlier transactions include AZ’s $1.8 billion acquisition of CinCor Pharma in 2023 , bringing in aldosterone-synthase inhibitor baxdrostat, now in Phase III alongside dapagliflozin, and a 2021 exclusive licence of Dogma Therapeutics’ first-in-class oral PCSK9-inhibitor program (advanced internally as AZD0780, Phase II). Thus, the British-Swedish multinational pharmaceutica … ost public venture into the aging space was its partnership with Alphabet to co-fund Calico, a biotechnology company aimed at understanding the underlying biology controlling aging. AbbVie partnered with Calico in 2014 and renewed the investment in 2018 and 2021 with an additional $500 million each. However, Calico has been shrouded in controvers
epm Therapeutics: Developing CBDA-based therapies for PWS | epm Therapeutics posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign in, yo
%PDF-1.7 %���� 3331 0 obj > endobj 3340 0 obj >/Filter/FlateDecode/ID[ ]/Index[3331 16]/Info 3330 0 R/Length 62/Prev 5063746/Root 3332 0 R/Size 3347/Type/XRef/W[1 2 1]>>stream h�bbd``b�T�_�3/�`�\S@J � !{H *a�d100�����` - endstream endobj startxref 0 %%EOF 3346 0 obj >stream h��W}PTU?ga�I���[d �%���"[b�2��Y�� va�'-��b����,ȇb �Q�5�S�b5ZQmE���iZ�t�}o?X?���v��{ι��; ���>@� �����(!f���dg��2ٙ[�2�d洘�Y���^fNd���TE�lٿ���gtܭ�/\� x+K����Ψ4|fT�,Fl�UK�r� �'/���,e�$Y5�|�=� ������j6J{\l����7��nE6\vG�ro��*N����;`c��r�P��xW���9� 7$K�֬�W�� �X->R�����Y݅Ot�Y�8�n�7�)�Q� … -06T11:26:27-05:00 2022-03-06T11:26:27-05:00 Adobe Illustrator 25.4 (Macintosh) application/pdf SB-Signature_white xmp.did:486f2e51-c7a4-40cb-8d6c-c095955f2d99 uuid:36e2a6a1-5228-0745-b977-5601af68470c uuid:5b3a6610-94cc-3742-a1e3-b66c21977ade proof:pdf uuid:01064172-e3c6-43a3-864a-6751f5cf4ebb xmp.did:e71b3e46-cb60-3e46-a4fb-1eb85312a5ef uuid:5b3a6610-94cc-3742-a1e3-b66c21977ade proof:pdf saved xmp.iid:e71b3e46-cb60-3e46-a4fb-1eb85312a5ef 2021-02-27T09:03:30+05:30 Adobe Illu … 02-27T09:03:34+06:30 2021-02-27T09:03:34+05:30 Adobe Illustrator 25.1 (Windows) application/pdf MRNA002_AR xmp.did:e71b3e46-cb60-3e46-a4fb-1eb85312a5ef uuid:01064172-e3c6-43a3-864a-6751f5cf4ebb uuid:5b3a6610-94cc-3742-a1e3-b66c21977ade proof:pdf uuid:13bf798b-df32-d647-9983-b8d60e664483 uuid:5b3a6610-94cc-3742-a1e3-b66c21977ade uuid:5b3a6610-94cc-3742-a1e3-b66c21977ade saved xmp.iid:e71b3e46-cb60-3e46-a4fb-1eb85312a5ef 2021-02-27T09:03:30+05:30 Adobe Illustrator 25.1 (Windows … OF�q%��Si�sv���؉�e�*=G�� ���ڱN�^z��J&pn�V�Q �[o���"��o���Uk���� s=� ju�rfpۢ���y\� �t��3s���8F���kO�6���&튢bh�\Jl,�5���q[-�+|8����rtU�Ȭu�"g��u\�)�2٪�gf#jy�xz ���k��"/x�I�}��GWW�S��L�/\c�%��";�;�c=���N�vg��6,ET�uN)�o� Q +_oe:��wDu}�y#�k��&3�M��S [��-q�7�p�{���vm�昘��X���_�����i۷h�� �F�rw�_��w�nh�QT�U�X���^���\� �?7�� �EY��5Y���Ϡю+�7��E�ZZ����\��� �Y4zx�;Mg�#�3�(�tSEک� �mSr�STf�7��I�EiH��yڱ�X��|C4s_ �E�@SU��s3�� (��ۮW>g� /]3s�/ �6�7&�Zx�Q�WG4+7lU�1� … ����+��}���H1�;ֽ|��F��^�&Z+�e�`�4���������\k��U�5ΩE�.K��,��b,w �B.�2�$�:���RFP :����Nr#�U��xd �[0�P�����]iؤ2�Ŕ��iT�� Aqb��e���k},�?`��KAP ���AB�6ʂ�� �;� �P9������xK��=Y⥀z(�E[�o��ۯ�fK��, >k)���eK�Ћ)�, *Ye� .v`g~P�Q2Q��k������"�ǝ���h ,�Fd0�F#;1�*�����z�et�4r͆x ��A}\� �=�G�m��R㨅��t;��Ȱ�*Nކ��)Ϋ�8a2'*���^gc�:]l��2��P�N���~����
Booster Ventures ABOUT FEATURES TEAM PORTFOLIO CONTACT US We Boost What We Touch Investing early in exceptional tech startups about us What We Do Booster joint venture is a team of experienced operators who are focused on cutting-edge tech startups. Our success has been driven by our hands-on approach. Each of the partners comes with a proven track record in multiple businesses and industries. We provide startups with all the necessary infrastructure to help them gain momentum and grow. We do so by offering end-to-end support through our unique value creation team and our ability to accompany
💵 Funding News: Booster Therapeutics Secures $15M Seed Funding to Transform Proteasome Activation Medicines! 💥 Berlin’s Booster Therapeutics is pioneering a new class of medicines to restore the… | Future Techly LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at a … 👇 🏛 Top 5 Public Rounds 1. Genmab — $5.5B Debt Financing ➝ Strategic move to fund its $8B acquisition of Merus N.V. . 2. Thermo Fisher Scientific — $2.5B Senior Notes ➝ Continued investment in gene and cell therapy platforms. 3. Royalty Pharma — $2B Senior Unsecured Notes ➝ Expanding its portfolio of royalty assets in late-stage therapeutics. 4. Cytokinetics — $650M Convertible Notes ➝ Strengthening its balance sheet for cardiovascular drug pipeline. 5. Avidity Biosciences … es. 🏆 Perfusion Medical Wins Crab Trap: Reston-based startup took home the top prize with therapy PM-208, while Chariot Biosciences earned $10K in CRO services. ⚗️ Advanced Research Projects Agency for Health (ARPA-H) GIVE Program: New initiative launched to revolutionize biomanufacturing for cell and gene therapies, addressing cost and complexity in production. 🏭 GSK Expands Rockville Manufacturing: Despite exiting its vaccines R&D hub, the pharma giant will invest par … ulator R-2487 into clinical testing for Sjögren’s disease. 🌟 PQE Group US Wins Award: Named “Best Life Sciences Company in Maryland” by the Stellar Business Awards for innovation, leadership, and industry impact. https://lnkd.in/gs4yMdmN 25 Like Comment Share Copy LinkedIn Facebook X To view or add a comment, sign in second scight 236 followers 8mo Edited Report this post The biopharma investment landscape remains robust! Key findings have been compiled from the Fierce Biote
%PDF-1.7 %���� 712 0 obj > endobj 724 0 obj >/Filter/FlateDecode/ID[ ]/Index[712 23]/Info 711 0 R/Length 73/Prev 1291850/Root 713 0 R/Size 735/Type/XRef/W[1 2 1]>>stream h�bbd``b`_ $���&�`i�@�i���B'�� H�r� q�����) �b``$���`� �� 5 endstream endobj startxref 0 %%EOF 734 0 obj >stream hޜU[PW�O�����@R�(�UB�J��� J"�0�/ D�V\@%�T��@/U�x�b7��ӗR;Ӿ���q�� �v:cϒh�8��������r�?{6'��W�R�" (Pa\U�^=� �-e�:;�n�z0W�L�Y�'n5uW/$.�E?f������?o}�TЙT�r.|�>g�Ɋ�?�,pխn�W�04=C�4!Ø� D|8��Z�3�Ñ(��a~���)�� �D�Q���c9#I��G���C�)�5���Q#�xN��D�%�I�xl G��'��ƈHc1%�0)&x���d�$N �XSj��)�� … 333333 Inches Cyan Magenta Yellow Black Default Swatch Group 0 Document AIRobin application/pdf Spiral proof:pdf uuid:701440b0-9c00-c043-9e5d-500160f93740 uuid:264a3b85-99df-a24c-9a26-32ecdf614ce6 Adobe PDF library 17.00 endstream endobj 72 0 obj >stream H���I@0��}�5�Db�-��b�(��:������x�����N� ^��y�\"(g >stream UWUXUXVXVXVYWYWYXZYZY[Z[ [\ \\ ]] ^^ _^ `_ a`!ba"cb#db$ec%gd%he&if'kg(lh)mi*oj+pk,rl-tm.uo/wp0yq1zr2|t3~u4�v6�x7�y8�z9�|;�} ��?��@��B��C��E��F��H��I� … N VɴŐ��&e��8�PvPB�c�w!��Ph,��b �������u�3 �%7�_��Y����� zf' � [� >stream application/pdf AppelSauce-Vector 2025-04-22T15:39:32-04:00 2025-04-22T15:39:32-04:00 2025-04-22T15:39:32-04:00 Adobe Illustrator 29.4 (Macintosh) uuid:2bc91d1b-ce7d-4a40-a00b-07bd86006db5 xmp.did:c81dbac9-f8d8-49f8-8276-73f3ddfc01bc uuid:5D20892493BFDB11914A8590D31508C8 proof:pdf uuid:7714bbb3-cb4b-9e4b-a7cc-ba1f08c54dbc xmp.did:09a6dae5-d973-4c6c-9883-0fe9bfce3a2a uuid:5D20892493BFDB11914A8590D3 … 50 179 72 C=0 M=27 Y=56 K=0 PROCESS 100.000000 RGB 252 211 165 Document AIRobin application/pdf Hands2 proof:pdf uuid:93b1eedd-45c3-8a43-8ad7-d1a3b0d72b69 uuid:b58602ac-8071-c64a-aeae-9834bfe90645 Adobe PDF library 17.00 endstream endobj 80 0 obj >stream ����Adobed��� '$''''$25552;;;;;;;;;; ####''',,, ####''',,,������"��� … T� �1�5� 4P���Qբ���!L�""bX�1�X�Z����� endstream endobj 81 0 obj >stream application/pdf Pumpkinseed 2025-04-22T16:00:48-04:00 2025-04-22T16:00:48-04:00 2025-04-22T16:00:48-04:00 Adobe Illustrator 29.4 (Macintosh) uuid:6f5f1d6f-efec-0d49-a3ae-7e207e3457a3 xmp.did:48ba735c-a149-4585-9ce5-5976dc8285e4 uuid:5D20892493BFDB11914A8590D31508C8 pr
Apollo Health Ventures Join us on LinkedIn for the latest news. Contact LP Login What we believe in what we invest in who we are latest from us Contact lp login We use cookies to improve the user experience. You can read more about our Cookie Policy here . Accept Building Next Generation Companies To Enhance Healthy Lifespan Apollo Health Ventures is a transatlantic early stage Venture Capital firm actively co-founding and investing in transformative healthcare companies targeting age-related diseases and aging itself. Learn more Biotechnology is the solution for a healthier lifespan and reduc
%PDF-1.7 %��љ 2 0 obj > /OCGs [] >> /Outlines 6 0 R /Pages 7 0 R /Type /Catalog /ADBE_FillSignInfo > >> endobj 5 0 obj > stream 2025-06-06T14:52:57+12:00 2025-07-21T13:28:39+12:00 Adobe InDesign 19.4 (Windows) 2025-07-22T15:27:53+12:00 application/pdf uuid:6242796d-fd4f-4129-8e4c-cf5dc369f0dc uuid:e3ec22b4-55ce-4b67-a7df-52ee58563905 Adobe Acrobat (64-bit) 25.1.20474 endstream endobj 72 0 obj > stream H�|WK��ܿS���7In��7� W^�x��� �r:KZ��k�����Ϝ��~��8d�3�6�d�o_6n9����� �:��gv����?�? ��Q�d���s᳇n���Yi o�,X�g�"l ﯷq�5��mT ҀT�:;�O+����y���q����[�PZG�8u4~Р���lJN0Z�X� 7 e������s�~5�
Diphtheria Acquired by U.S. Citizens in the Russian Federation and Ukraine -- 1994 Persons using assistive technology might not be able to fully access information in this file. For assistance, please send e-mail to: [email protected] . Type 508 Accommodation and the title of the report in the subject line of e-mail. Diphtheria Acquired by U.S. Citizens in the Russian Federation and Ukraine -- 1994 Epidemic diphtheria has reemerged in 14 of the 15 New Independent States (NIS) of the former Soviet Union (1); during 1994, a provisional total of 47,802 cases and 1746 deaths from diphtheria were repor
XBRL Viewer Please enable JavaScript to use the EDGAR Inline XBRL Viewer.
Active immunization of children with leukemia and other malignancies Active immunization of children with leukemia and other malignancies Leuk Lymphoma . 1993 Feb;9(3):177-92. doi: 10.3109/10428199309147369. Authors D Ridgway 1 , L J Wolff Affiliation 1 Division of Pediatric Hematology and Oncology, Oregon Health Sciences University, Portland. PMID: 8471977 DOI: 10.3109/10428199309147369 Abstract Active immunization against measles, Haemophilus influenza B, tetanus, diphtheria, hepatitis B, influenza, poliomyelitis, and, when indicated varicella and pneumococcus induces long-lasti
Booster Therapeutics: $15 Million Raised To Develop New Class Of Proteasome Activator Medicines VC PE M&A Asset Management Law Firms Profiles Contact × Search Pulse 2.0 Booster Therapeutics: $15 Million Raised To Develop New Class Of Proteasome Activator Medicines By Amit Chowdhry • Oct 13, 2024 Booster Therapeutics: $15 Million Raised To Develop New Class Of Proteasome Activator Medicines Booster Therapeutics, a biotechnology company pioneering a new class of proteasome activator medicines to treat neurodegenerative and other diseases, launched with the support of a $15 million fun … ry to drive restoration of protein homeostasis in various disease contexts. The application potential of this therapeutic frontier is highly attractive, and given the broad-spectrum activity of proteasome activators, we see opportunities for both monotherapy and combination approaches where increased proteasome activity may enhance the efficacy of other therapeutics.” -Dr. Patrick Trojer, Chair of Booster’s Board of Directors and Chief Executive Officer of TRIANA Biomedicines
Booster Labs S.A.S. | Horizon Europe Cluster 4 Digital Matchmaking Platform Horizon Europe Cluster 4 Digital Matchmaking Platform Home Our events and sessions Participants Marketplace Services Contacts & Help Log in Register Log in Register Log in Register Booster Labs S.A.S. Small or Medium Enterprise (SME) booster-labs.com Antony, France 1 profile visit About Representatives About Booster Labs has the mission to support the acceleration of DeepTech start-ups. The uniqueness of our approach consists in a “collaborative acceleration” that aims to leverage and align, based on the partnershi
Booster Capital Acquires Stake in Artesana, Romanian Dairy Brand | Booster Capital posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign … mania. This is the second transaction of Booster Capital in 2025. In April, the fund invested in Bisbags, one of the leading paper packaging producers in Romania, alongside the founder and CEO Iulia Sullivan. The team of Booster Capital has extensive experience in developing market leaders in partnership with entrepreneurs, in a variety of industries such as food production (ViaTrend), branded goods (Fabryo-Atlas Paints), IT services (RBC Group) or financial services (Kiwi Fi … financial services (Kiwi Finance). Booster Capital is a regional private equity fund with a target size of EUR 100 million, launched in 2024. The largest commitment to the fund – EUR 30 million, comes from the European Union – NextGnerationEU, with the financial backing of the Government of Romania under the Romanian Recovery Equity Fund, a program managed by the European Investment Fund. Luxembourg, July 2025 158 7 Comments Like Comment Share Copy LinkedIn Facebook X Martyn … ed to acquire ~80% of Valencia-founded Hundred Burgers, launching its new €250m fund, Buenavista Buy Out III (typical deal size €25–30m). Founders retain ~20% and continue leading the vertically integrated chain, which crafts bread and minced beef in two central kitchens (Valencia, Madrid). • ProA Capital sold Avioparts - A Proponent company to US distributor Proponent . Avioparts, supplier of aircraft tires, lubricants, chemicals and logistics solutions, reached €66m revenue … F II Lightbulb (Cayman), Schroders Capital, Azim Premji-backed PI Opportunities Fund, Macritchie Investments, Kedaara Capital, and Alpha Wave Ventures." Wakefit, Lenskart Eye IPO As part of the new issue component, the biggest seller of prescription eyeglasses in Gurugram may also think about collecting up to Rs 430 crore in a pre-IPO transaction
Novo Holdings Launches Portfolio Company Booster Therapeutics to Advance New Class of Small Molecule Proteasome Activator Therapeutics Accessibility Statement Skip Navigation Resources Investor Relations Journalists Agencies Client Login Send a Release News Products Contact Search Search When typing in this field, a list of search results will appear and be automatically updated as you type. Searching for your content... No results found. Please change your search terms and try again. News in Focus Browse News Releases All News Releases All Public Company English-only News Releases Overview Mu … tform Login ProfNet Data Privacy Do not sell or share my personal information : Submit via [email protected] Call Privacy toll-free: 877-297-8921 Contact PR Newswire Products About My Services All News Releases Platform Login ProfNet Call PR Newswire at 888-776-0942 Terms of Use Privacy Policy Information Security Policy Site Map RSS Cookies Copyright © 2026 Cision US Inc. --> -->
Booster Therapeutics Awarded Grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) to Advance New Class of Proteasome Activator Medicines Towards First-in-Human Phase 1 Study - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUB … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Press Releases Booster Therapeutics Awarded Grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) to Advance New Class of Proteasome Activator Medicines Towards First-in-Human Phase 1 Study November 14, 2025 | 3 min read Twitter LinkedIn Facebook Email Print Booster Therapeutics is developing a novel … ns in cells, which are a major driver of Parkinson’s and other complex diseases Grant will further research into activators of the 20S proteasome, which reverses proteasome dysfunction to enable recognition and degradation of a wide range of undesirable proteins BERLIN--(BUSINESS WIRE)--Booster Therapeutics, a biotechnology company pioneering a new class of proteasome activator medicines to treat neurodegenerative and other diseases, announced today it has received a research … eurodegenerative and other diseases, announced today it has received a research grant of $5 million dollars from The Michael J. Fox Foundation for Parkinson's Research (MJFF) as part of MJFF’s Therapeutics Pipeline Program. This will support the development of small molecule therapeutics that re-activate the cellular quality control machinery of proteasomes. “Developing treatments that target the root biological drivers of Parkinson’s is essential to delivering meaningful ben … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Practice Booster Acquired by eAssist Dental Solutions News All News Industry News The Week in Review 5Ws Live Events New Dental Products Media Product Bites Product Insights Test Drives Live Show Coverage Mastermind Therapy in 30 Minutes 5Ws Videos Technique in 2 Minutes Dental Product Presentations Expert Interviews Podcasts Issues Dental Products Report Dental Lab Products Resources Sponsored Content Sponsored Resources eBooks Job Board OTC Guide Directory Continuing Education CE Webinars CE Articles Virtual Events Choose Specialty Catapult Education Cement and Adhesives Cosmetic Dentistry D
--> Community Sponsorship | Johnson Bands top of page Cart HOME ABOUT US DIRECTORS BAND BOOSTERS PRIVATE LESSON STAFF CALENDAR I WANT TO . . . GET CONNECTED VOLUNTEER LEARN ABOUT EVENTS PAY BAND FEES READ THE FAQ'S SEE DOCUMENTS & RESOURCES I AM A . . . PARENT STUDENT FUTURE STUDENT COLOR GUARD PROSPECTIVE COLOR GUARD SHOP All products Spirit Gear & Merchandise TMF STORE Meal Plans FLY A FLAG Community Sponsorship Membership Support the Jag Band SPONSORSHIPS OUR SPONSORS PHOTOS Band Fees More Use tab to navigate through the menu items. Sponsorship View our 2025-2026 Sponsor
Private equity firm Booster Capital acquires majority stake in Romanian distributor of vet products | Romania Insider Skip to main content 23°C Bucharest, RO 07:53 Search 23°C Bucharest, RO 07:53 Search Main navigation - v3 Latest News Interviews Analyses Opinions Podcasts Video Photo Charts Business Capital Markets Real Estate M&A Startup Agriculture Macro Tech HR Energy Transport Finance Legal Society Justice Politics Defense Administration Education Healthcare Environment Diversity CSR Life Sports Culture Events Expat life Living in RO New in town Romanians abroad Discover RO Travel Nat … per transaction in companies across Romania and Central and Eastern Europe. The fund’s portfolio also includes companies such as the local dairy manufacturer Artesana and the Romanian paper packaging producer Bisbags. [email protected] (Photo source: V ichaya Kiatyingangsulee/Dreamstime.com ) Normal M&A Private equity firm Booster Capital acquires majority stake in Romanian distributor of vet products 29 April 2026 Simona Fodor Like this article? Share it with yo … per transaction in companies across Romania and Central and Eastern Europe. The fund’s portfolio also includes companies such as the local dairy manufacturer Artesana and the Romanian paper packaging producer Bisbags. [email protected] (Photo source: V ichaya Kiatyingangsulee/Dreamstime.com ) Normal M&A Private equity firm Booster Capital acquires majority stake in Romanian distributor of vet products 29 April 2026 Simona Fodor Like this article? Share it with yo … per transaction in companies across Romania and Central and Eastern Europe. The fund’s portfolio also includes companies such as the local dairy manufacturer Artesana and the Romanian paper packaging producer Bisbags. [email protected] (Photo source: V ichaya Kiatyingangsulee/Dreamstime.com ) Normal Recommended stories 23 June 2026 Politics Romania’s government crisis deepens after Parliament rejects Veștea cabinet 22 June 2026 Events Carlos Saiz’s Lionel wins top pr … der Sorin Grindeanu for prime minister 24 June 2026 Finance Romanian investment fund Fortech Ventures changes name to Nucleo Ventures, launches EUR 34 mln fund 24 June 2026 Events European Parliament hosts "The Infinite of Brâncuşi" exhibition honoring Romanian sculptor 24 June 2026 Finance Romania cuts RRF by EUR 1.2 bln to EUR 20.2 bl
Bisbags Acquired by Booster Capital | M&A News | Signalbase Signalbase Signals Pricing API docs Login Get API access Login Get API access Toggle menu M&A news · Published July 17, 2025 Booster Capital Acquires Bisbags to Enhance Sustainable Packaging Solutions Bisbags acquired by Booster Capital Acquisition Packaging Get the full Bisbags company profile Access contacts, investors, buying signals & more Open in Dashboard Acquired Bisbags Wholesale Undisclosed amount July 17, 2025 Acquirer Booster Capital Financial Services # Booster Capital Acquires Bisbags: A Strategic Move in the
--> Business Circle - Drama Booster Sponsorship Donation | Steelecanyonplayers top of page Log In ABOUT CTE Stage Technology Pathway COURSES CTE Professional Theatre Arts Pathway STAFF TICKETS NEWS AUDITION THESPIAN/CLUB NEWS AWARDS CALENDAR 2025-2026 SEASON 2024-2025 SEASON 2023-2024 Season 2022-2023 SEASON 2021-2022 SEASON 2020-2021 SEASON 2019-2020 SEASON SHOW ARCHIVES WEB STORE BOOSTERS CONTACT More Use tab to navigate through the menu items. Business Circle - Drama Booster Sponsorship Donation Help support the Steele Canyon Players program by becoming a Drama Booster Club sponsor! All don
Random Buys - YouTube Info Presse Urheberrecht Kontakt Creator Werben Entwickler Impressum Verträge hier kündigen Nutzungsbedingungen Datenschutz Richtlinien & Sicherheit Wie funktioniert YouTube? Neue Funktionen testen © 2026 Google LLC
%PDF-1.4 %���� 1 0 obj > endobj 3 0 obj > endobj 5 0 obj > stream x�}��J���Ԃ(�� 28�h��iRpi"�V��S��A�OHS�tspu+.���c(��#����AR�x�������@����?��F�[V[�G@`*� dK��$���O.K o� @��6 `�O�,f'�˘O� asx�0A�6�vf� �8���{c7��%op�Z�:u� ���Q�� ���0Q٣F �*��Ԑ(�S����DGACAa�j�g�rx��]��s PxM�� ����c� vhO� > stream x����s\ٕ �3VK"�d���5�*�#�����Ш��ª�=� ��k��VO; ��8uDO��V��(Kf���w��[ִ��A�(�_� d���s�@!�B!�B!�B!�B!�B!�B!�B!�B!�B!�B!�B!�B!�B!�B!�B!�B!�B!�B!�B!�B!�B!�B!�B!�B!�B!�B!�B!�B!�B!�B!�B!�B!�B!�B!�B!�B!
Hardware acquired 🫡 thanks to Booster Robotics. Now I finally have something I can use for imitation learning. Thanks to Gijs de Jong for building out the Rerun integration | Pablo Vela LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings .
Cell Therapy Weekly: Acquisition to Advance CAR-T Therapy for Multiple Myeloma - RegMedNet Skip to main content RegMedNet is part of Taylor & Francis Group. Taylor & Francis About us Our journals Our Digital Hubs Taylor & Francis Group is a trading division of Informa that operates through various Informa legal entities including, but not limited to, Informa UK Limited, with the registered address at 5 Howick Place, London, SW1P 1WG, UK. Taylor & Francis Home Our journals Our journals Journal content Journal articles Follow us on social media Topics CAR-T Stem cells Cell therapy Gene th … ng specificity and binding affinity. The FDA has accepted the Biologics License Application for anito-cel, with a decision expected by December 2026. The transaction, approved by both companies’ boards, is set to close in the second quarter of 2026, pending regulatory approvals and shareholder agreements. Read more First patient dosed in study of next-generation CAR-T therapy with IL-12 booster A2 Biotherapeutics has dosed the first patient in its EVEREST-2 study, evaluating
Booster’s Private Land & Property Portfolio buys kiwifruit orchard Skip to content Close Products & Services KiwiSaver Booster KiwiSaver Scheme KiwiSaver Basics Fees & Charges KiwiSaver Calculator How to Make KiwiSaver Contributions Get the government contribution Get a first home withdrawal Making a withdrawal Transfer into KiwiSaver Accidental Death Cover Investments Booster Investment Funds Tahi Fund Booster Innovation Fund Private Land and Property Fund NEW Debit Card mybudgetpal Superannuation Ethical Investing Insurance Financial advice Why Booster About us Our Team Careers B … into KiwiSaver Accidental Death Cover Investments Booster Investment Funds Tahi Fund Booster Innovation Fund Private Land and Property Fund NEW Debit Card mybudgetpal Superannuation Ethical Investing Insurance Financial advice Why Booster About us Our Team Careers Booster Foundation Tools & Info Tools Documents Blog FAP License FI License Contact Join Login Quick results for "{search_term}" KiwiSaver Make saving for your first home or retirement easy Superannuation Transf … p; Debit Card Save and spend better! Savvy. It’s your money, smarter. Insurance Apply for life insurance – cover from $20k to $2m mybudgetpal Sort your spending and see where your money is going Financial Advice Get tailored advice to help you reach your financial goals About us We’re not your traditional financial services company. Find out why.. . Our Team We’re on a mission to build the financial resilience of every New Zealander Careers Join a team of like-minded people s … s Private Land & Property portfolio . Booster’s Private Land & Property Fund, which gives retail investors access to the portfolio, listed on the NZX last week. The purchase of a kiwifruit orchard provides further geographic and crop diversification to the fund, which was previously invested in viticulture. The Private Land & Property Fund is Booster’s solution for savers struggling with low interest rates. It aims to deliver average annual returns of 8% ove … to deliver average annual returns of 8% over a seven-year horizon. This is the fund’s first addition in Northland, adding to its portfolio of land in Marlborough, Nelson and Hawkes Bay . “Kiwifruit is New Zealand’s most successful export crop. Our fertile soils and excellent growing conditions produce a premium crop that command high inte
2026-27 Booster Club Sponsorship - Stony Point Football Booster Club Skip to content Stony Point Football Booster Club Stony Point Football Booster Club Teams Menu Toggle Schedules Menu Toggle 2026 Varsity Schedule 2026 Junior Varsity Schedule 2026 Freshman Schedule Rosters Menu Toggle 2025 Varsity Roster 2025 Junior Varsity Roster 2025 Freshman Gold Roster 2025 Freshman Blue Roster 2025 Freshman Combined Roster Coaches Student Trainers and Film Crew Membership Menu Toggle 2026 Booster Club Executive Board Members 2026 Stony Point Football Booster Club Members Join the Club Volunteer Opportuni … Austin) 2022 STP Football MIXTAPES (FLXATX) 2021 STP Football MIXTAPES (FLXATX) Scholarship Recipients Menu Toggle 2026 Recipients 2025 Recipients 2024 Recipients 2023 Recipients 2022 Recipients 2021 Recipients 2020 Recipients 2019 Recipients Tigers In College Donate Menu Toggle Donate to Stony Point Football Company Match Program Shop Stony Point Football Booster Club Main Menu Teams Menu Toggle Schedules Menu Toggle 2026 Varsity Schedule 2026 Junior Varsity Schedule 2026 Fr … Austin) 2022 STP Football MIXTAPES (FLXATX) 2021 STP Football MIXTAPES (FLXATX) Scholarship Recipients Menu Toggle 2026 Recipients 2025 Recipients 2024 Recipients 2023 Recipients 2022 Recipients 2021 Recipients 2020 Recipients 2019 Recipients Tigers In College Donate Menu Toggle Donate to Stony Point Football Company Match Program Shop 2026-27 Booster Club Sponsorship Registration 2026-27 Booster Club Sponsorship $ 500.00 – $ 5,000.00 Price range: $500.00 th … tball by choosing a sponsorship package below. Your generous contribution helps fund essential equipment, events, and other team needs throughout the season—thank you for being a vital part of our success! Payments are accepted via credit card or PayPal. To pay by check or another method, please contact us at [email protected] . Sponsorship Level Choose an option MVP ($5000) Diamond ($2500) Platinum ($1500) Gold ($1000) Blue ($500) Clear Company Name * Website Insta
Acquisition Gateway Please enable JavaScript to continue using this application.
ctDNA Dynamics and Mechanisms of Acquired Resistance in Patients Treated with Osimertinib with or without Bevacizumab from the Randomized Phase II ETOP-BOOSTER Trial ctDNA Dynamics and Mechanisms of Acquired Resistance in Patients Treated with Osimertinib with or without Bevacizumab from the Randomized Phase II ETOP-BOOSTER Trial Clin Cancer Res . 2024 Nov 15;30(22):5180-5191. doi: 10.1158/1078-0432.CCR-24-0932. Authors Ross A Soo 1 , Urania Dafni 2 3 , Ji-Youn Han 4 , Byoung Chul Cho 5 , Ernest Nadal 6 , Chong Ming Yeo &n